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ABSTRACT OF THE DISSERTATION 
Enhanced Detection of Drug-induced Cardiotoxicity in Human Stem Cell-Derived 
Cardiomyocytes Using Optical Flow, Biomimetic Substrates, and Machine Learning 
by 
Eugene Lee 
Doctor of Philosophy in Biomedical Engineering 
University of California, Irvine, 2017 
Professor Michelle Khine, Chair 
 
 Current preclinical screening methods are ineffective at detecting cardiotoxicity: 30% of drug 
attritions are attributed to drug-induced cardiotoxicity. With recent advancements in stem cell 
technologies, human pluripotent stem cells-derived cardiomyocytes (hPSC-CM) can now provide a 
physiologically relevant in vitro model of the myocardium. Availability of such cells has led to the 
emergence of various platforms that utilize them. However, current platforms still encounter challenges 
that deter their adoption for commercial use. One issue is hPSC-CMs exhibit fetal-like phenotypes; 
screening with them leads to unpredictable results that don’t accurately represent cardiotoxicity in 
adults. Another persistent challenge is the need to develop a simple and reliable method to measure key 
electrophysiological and contractile parameters. In addition, analytical approaches need to be created 
for accurate and automated detection of cardiotoxicity from platform readouts. In this thesis, strategies 
that collectively form a platform are described to address these issues.  
Alignment of hPSC-CMs has been shown to regulate sarcomere orientation, produce stronger 
contractile forces, and cause anisotropic action potential propagation. We demonstrate that biomimetic 
substrates with topographical alignment cues (uniaxial and multi-scale ‘wrinkles’) can be fabricated by 
using pre-stressed thermoplastic shrink film. These wrinkles recapitulate the anisotropic nature of the 
xi 
 
ECM of the native myocardium. When aligned on these substrates, hPSC-CMs exhibited a more 
sensitive response to cardioactive compounds than their unaligned counterparts.  
Using brightfield microscopy and optical flow, contractility of hPSC-CMs exposed to 
compounds can be monitored in a non-invasive and inexpensive manner. Furthermore this brightfield 
technique was readily applied to cardiac constructs of various tissue geometries, ranging from 2D 
monolayers to 3D cardiac organoids. For improved and automated analysis, we mated the brightfield 
technique with supervised machine learning. The machine learning provides a singular quantitative 
index that summarizes the impact of multiple parameters, and thus simplifies the assessment of drug 
effects on hPSC-CMs. Through the evaluation of several cardioactive drugs with dissimilar effects, this 
paired method was comparable – and even superior to – a fluorescence-based detection scheme 
common in commercially available systems. The machine learning was further leveraged for the 
analysis of a cardiac tissue strip platform. A model of drug classes was created and successfully 
predicted the mechanistic action of an unknown cardioactive compound.
1 
 
CHAPTER 1: Introduction 
1.1 Motivation  
 The current state of drug development is inefficient, prolonged, and costly. Only 1 out of 
every 5,000 compounds available at the drug discovery stage will achieve Food & Drug 
Administration (FDA) approval, which averages about 14 years at a cost of $1.5 billion.
1
 A 
significant proportion of the overall cost for drug development is attributed to withdrawal of 
drugs in clinical phases or post-FDA approval, 30% of which is related to cardiotoxicity.
2
 For 
example, the diuretic drug cisapride’s undetected cardiotoxic effects resulted in 175 deaths and 
386 cases of serious ventricular arrhythmia before it was removed from the market in 2000.
3
 This 
suggests that the current methods of drug screening for detecting cardiotoxicity are ineffective.  
The advent of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) creates 
the possibility of a better in vitro model of the human myocardium for various applications 
including drug screening.
4–7
 However human pluripotent stem cell-derived cardiomyocytes 
(hPSC-CM) exhibit embryonic-like phenotypes in terms of electrophysiological properties, 
contractility, and structural development.
8,9
 Different phenotypes may result in disparate drug 
responses and affect the accuracy of hPSC-CM as an in vitro model.  
Another challenge in the adoption of hPSC-CMs for drug screening purposes is the 
shortcomings of current detection assays.  Invasive methods, such as patch clamping, are 
traditionally limited to single cell analysis, and have proven difficult for high-throughput 
applications. Attempts to incorporate patch-clamping into high-throughput and commercial use 
are limited by cell membrane quality.
10
 In addition, the instability of the seals prevents extended 
or longitudinal studies.
11,12
 Fluorescence-based optical methods such as voltage and calcium 
sensitive dyes provide non-invasive means to observe electrophysiological properties of hPSC-
2 
 
CMs.
13
 However, these dyes can impact cell function, and therefore are not suitable for 
prolonged studies. Furthermore, both dyes and genetically encoded indicators are subject to 
photobleaching effects.
14,15
 Microelectrode arrays (MEA) have high-throughput capabilities, but 
require a cluster of CMs for accurate electrical signals.
16,17
 Similarly, impedance-based 
measurements offer non-invasive, high-throughput methods of drug screening, but are limited to 
monolayer cell cultures.
18,19
  
While these methods of operation may vary, the readouts of systems are predominantly 
composed of an array of parameters that describe the behavior or shape of individual contractile 
events. Combining this with the number of experimental conditions (e.g. various pacing 
frequencies or drug concentrations) can yield high-dimensional datasets that make it difficult to 
draw comprehensive conclusions. In addition, as these platforms are meant for high-throughput 
use, the analysis needs to be automated. Such requirements indicate that traditional methods of 
pre-selecting one or a few parameters for statistical analysis may not be adequate. By selectively 
examining a few parameters independently of one another, there is a risk of not detecting 
information that differentiates the behavior of normal hPSC-CMs from those exposed to 
cardioactive compounds. Thus, this works aims to enhance the detection of drug-induced 
cardiotoxicity in hPSC-CMs by addressing the challenges faced by current screening platforms. 
 
1.2 Overview of dissertation 
 The dissertation is structured as follows. Chapter 2 highlights the combination of 
brightfield microscopy, optical flow and post-processing techniques to monitor contractile 
behavior of cardiomyocytes when exposed to cardioactive compounds. In Chapter 3, the effects 
of biomimetic wrinkled substrates on cell alignment and hPSC-CM response to cardioactive 
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compounds are discussed. In Chapter 4, we demonstrate a method to adapt the brightfield 
technique and biomimetic substrates for high-throughput capabilities. This method entails a 
chemical approach that patterns multiple islands of cardiomyocytes onto the surface of a single 
substrate. Chapter 5 examines the application of supervised machine learning, in particular 
Support Vector Machines, to the automated analysis of data generated from cardiotoxicity 
screening platforms. The algorithms are able to determine if a compound is cardioactive and 
also, create a drug classification model that can predict an unknown cardoactive compound’s 
mechanistic action. In Chapter 6, the brightfield technique is applied to 3D cardiac organoids and 
provides spatial information that is not available in current pressure readouts. This information 
may be beneficial in the screening of compounds that disrupt electrical propagation on cardiac 
surfaces. We conclude with a discussion of future directions of this work in Chapter 7. 
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CHAPTER 2: Brightfield acquisition of human stem cell-derived 
cardiomyocytes 
2.1 Introduction 
 The shortcomings of current assays to quantify contractile behavior of cardiomyocytes 
have been one of main challenges in the adoption of human pluripotent stem cell-derived 
cardiomyocytes (hPSC-CMs) for the screening of drug-induced cardiotoxicity. Brightfield 
microscopy provides a possible solution as it is non-invasive and allows for long-term 
monitoring of cardiomyocytes. In addition, brightfield acquisition requires minimal and 
inexpensive equipment that is suitable for high-throughput use.  The concept of using image-
based analysis to quantify cardiomyocyte beating dynamics has been explored by various 
research groups.
7,20,21
 However, these studies have all required the need for custom cell 
culture apparatuses. More recently, research groups have investigated brightfield-based 
methods that are widely applicable to both standard cell culture apparatuses, such as a 384-
well cell culture plates, and custom ones.
22–29
 These respective methods have all demonstrated 
the feasibility of tracking the contractile behavior of cardiomyocytes and extracting out 
quantitative parameters to describe the apparent motion. Maddah et al. validated the 
practicability of using brightfield microscropy to monitor contractile behavior of 
cardiomyocytes in various setups: monolayer, cardiosphere and single cell.
30
 There are 
primarily two strategies in achieving image-based analysis: (i) methods that derive signals 
based on pixel differences or derivatives between frames and (ii) methods that derive signals 
based on generated motion vectors. 
Our platform leverages the benefits of brightfield microscopy and employs a vector-
based analysis, optical flow paired with post processing techniques. The rationale behind this 
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choice will be apparent in the following sections of this chapter. In addition, this chapter will 
explore two post processing techniques to augment the information derived from the optical 
flow-generated vectors. Lastly, our brightfield technique does not require custom cell culture 
apparatuses and can be applied to various tissue formats, ranging from monolayers to 3D 
cardiac models.  
 
2.2 Optical flow 
 Optical flow is often defined as the distribution of apparent velocities of the brightness 
patterns of an image. When applied to a video or sequences of image frames, velocities of 
objects in the video can be estimated. Optical flow makes two key assumptions: 1) apparent 
brightness of moving objects is constant between frames and 2) the movement of each image 
pixel is small.
31
 Based on those assumptions, in a regular two dimensional image, the image 
brightness constancy equation (Eq. 1) can be derived: 
   𝑰(𝒙, 𝒚, 𝒕) = 𝑰(𝒙 + 𝜟𝒙, 𝒚 +  𝜟𝒚, 𝒕 + 𝜟𝒕)  (1) 
𝑰 represents the intensity.  
Given the intensity is constant, the total derivative of Eq 1 can be set to 0, resulting in Eq. 2: 
    
𝒅𝑰(𝒙(𝒕),𝒚(𝒕),𝒕)
𝒅𝒕
=  
𝝏𝑰
𝝏𝒙
𝒅𝒙
𝒅𝒕
+  
𝝏𝑰
𝝏𝒚
𝒅𝒚
𝒅𝒕
+   
𝝏𝑰
𝝏𝒕
 = 𝟎  (2) 
Eq. 2 can be re-written with 
𝝏𝑰
𝝏𝒙
 as 𝑰𝒙 , 
𝝏𝑰
𝝏𝒚
 as 𝑰𝒚, 
𝝏𝑰
𝝏𝒕
 as 𝑰𝒕  , 
𝒅𝒙
𝒅𝒕
 as 𝑢, and 
𝒅𝒚
𝒅𝒕
 as 𝑣 (Eq. 3) 
 𝑰𝒙𝑢 +  𝑰𝒚𝑣 +   𝑰𝒕 = 𝟎   (3) 
Where 𝑢 and 𝑣 represent the displacement or vector in the x- and y-direction. 
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As seen in Eq. 3, 𝑢 and 𝑣 represent two unknown variables that cannot be solved with only one 
equation. Another constraint or equation would be necessary. This requirement is commonly 
referred to as the aperture problem.
32
 
 One of the most common solutions to the aperture problem is using the Horn-Schunck 
(HS) method.
33
 The HS method assumes smoothness among the image, meaning that areas of a 
moving object will tend to move together. As a result, optical flow fields with small gradients 
should be preferred to those with large gradients or distortions in the image. This is primarily 
implemented with introducing two energy terms: 𝑒𝑠 as departure from smoothness and 𝑒𝑐 as the 
optical flow constraint equation term. The goal of the HS method is then to minimize the linear 
combination of 𝑒𝑠 + 𝜆𝑒𝑐 in order to solve for 𝑢 and 𝑣, the optical flow field. 
 
2.3 Quantification of contractile behavior 
2.3.1 Optical flow analysis 
 To demonstrate the use of optical flow in quantifying contractile behavior of hPSC-CMs, 
brightfield videos of monolayer cardiomyocytes in an open perfusion microincubator were 
captured with QIClick CCD camera under two conditions: 1) 7 frames per second (fps) at a 
resolution of 1392x1040 pixels and 2) 20 fps at a resolution of 696x520 pixels. The images of 
the videos were then processed with an optical flow algorithm, which generated vectors that 
were representative of the hPSC-CM motion.
34,35
 The implemented optical flow algorithm was 
developed by Sun et al. and is based on the Horn-Schunck method described in Section 2.2. The 
algorithm resulted from the optimization of the HS method with the combination of common 
image processing techniques. Sun et al. showed that the HS method could be improved by three 
modifications: 1) changing the penalty function from HS penalty, ρ(x) = x2 to the Charbonnier 
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penalty, ρ(x) = (x2 + ϵ2)α, where α ≤ 0.5, 2) implementing a spline-based interpolation scheme 
and 3) using a median filter that examines and incorporates non-local terms.
34
 
 When the magnitudes of the generated vectors were plotted over time, the vectors were 
able to capture both the contraction and relaxation phase of a contractile event. For each beat, 
there were two distinct peaks that were followed by a resting phase if the beating frequency was 
low enough. To ensure that optical flow and its generated vector could assess changes to 
contractile behavior of cardiomyocytes, human embryonic stem cell-derived cardiomyocytes 
(hESC-CMs) were exposed to E-4031, a known human Ether-à-go-go-Related (hERG) K
+
 
channel blocker. The plot of vectors’ normalized displacements (relative magnitude) distinctly 
showed a delayed extension of specifically the relaxation phase when 30 nM of E-4031 was 
administered to hESC-CMs (Figure 2.1 A). This extension was expected as the inhibition of the 
hERG K
+ 
channel, which contributes to the rapid repolarization of the cardiomyocytes, prolongs 
the QT interval.
35
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Figure12.1 Optical flow vectors capturing cardioactive effects. A) Drug screen of E-4031, a potassium 
channel blocker known for prolonging the QT interval by delaying the rapid repolarization in 
cardiomyocytes. Solid line is without E-4031, and dashed line is with 30 nm of E-4031. An extended 
relaxation curve was seen when 30 nM of E-4031 was applied. B) Drug screen of isoproterenol, a β-
adrenergic agonist. The blue color represents contraction peak, and red color represents relaxation peak. 
At higher concentrations of isoproterenol, such as 10 nM, multiple phases were embedded within a 
perceived singular peak.  
 
2.3.2 Post optical flow contraction analysis 
 As a means to quantify matrices containing the x- and y-axis components of generated 
vectors and subsequent changes to hPSC-CMs when exposed to cardioactive compounds, an in-
house MATLAB software was created for post optical flow contraction (pOFC) analysis. The 
goal of the software was to compute duration, frequency, synchronicity, orientation, and 
acceleration of each contraction or contractile event.  
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To begin this post optical flow contraction (pOFC) analysis, the user will need to input a 
noise threshold, degree of error, time interval, and starting frame number into the guided user 
interface. The noise threshold refers to the cutoff value; if the maximum value in the grid of cells 
is below the cutoff, it is considered to be noise, and is assigned a value of zero. As seen in 
Figure 2.2A, the degree of error represents the flexibility in determining the stage of a 
contraction (i.e. contraction vs. relaxation). The time interval is the time between each 
consecutive frame. The starting frame number allows user to eliminate partial contractions. 
After the inputs have been submitted, the software calculates the occurrences of 
contraction and relaxation in each individual grid for the entire movie duration. Instead of the 
magnitude values, categorical variables are used when determining the number of contraction 
and relaxation occurrences in each grid. The cells within the grids are either contracting 
(represented by a value of 1), relaxing (a value of −1), or at rest (a value of 0). To determine 
when cells are at rest, a resting threshold is calculated for each individual grid using the 
following equation: Resting Threshold = Minimum Trough + 0.25 × (Maximum 
Peak − Minimum Trough). If the magnitude vector for a given time frame in a grid is below the 
resting threshold, then the cells within that grid for that specific time frame are deemed at rest. 
With the input of the starting frame number, the software searches for the first sign of a 
contraction and assigns the grid a value of 1 for that time frame. The vector direction of the same 
grid in subsequent time intervals is then compared to the previous time interval. If the direction 
of the vector is opposite of that in the previous frame and within the degree of error, and has a 
magnitude value above resting threshold, the cells in the grid are identified as in the relaxing 
stage, a value of −1. 
10 
 
A complete occurrence is defined as a contraction, relaxation and resting phase in 
sequence for each grid. If a grid does not have a complete occurrence throughout the entire video 
acquisition, then the grid is deemed insignificant and not considered in any of the calculations. 
The grid size is set such that any local cluster of beating cells is represented by multiple grids. 
After the software converts all grids into categorical values and filters out insignificant grids, the 
average duration and average frequency of each grid are calculated (Figure 2.2B). The 
frequency is defined as the number of complete occurrences per second. The duration of a 
complete occurrence is defined as the time between the first time interval where contraction 
occurs and the last time interval that exhibits relaxation. The software measures synchronicity 
among the occurrences of grids with the phase difference analysis. This analysis is done by 
taking the most popular pattern of occurrences and calculating the difference between this 
pattern and all the other patterns. The orientation of the grids is measured by computing the ratio 
between the sum of magnitudes for all y-axis components (of optical flow vectors) and the sum 
of magnitudes of all x-axis components over all time frames. The software also determines the 
acceleration of each grid by calculating the change of displacement over the change of time. 
 
Figure22.2 Post optical flow contraction analysis. A) Degree of error represents the flexibility in 
determining whether a subsequent contraction/expansion occurrence has the same or opposite direction of 
the reference vector, the previous occurrence, or is simply noise. The direction of all vectors is 
represented by plotting the real parts of arctangent of the x- and y-vectors on a unit circle. For example, if 
the degree of error is π/4 (right image in A) and the reference vector (RV) indicated in red represents a 
grid in the contraction stage, a subsequent vector (SV) that represents the next time frame and is in the 
direct opposite quadrant would mean the grid is now in the relaxation stage (assuming all values are 
0
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above resting threshold). However, if the SV lies in the gray quadrants, they are deemed noise. If the s.v. 
is in the same quadrant as the RV, then the grid is still in the contraction phase. For a degree of error of 
π/2 (left image in A), SVs have to be regarded as the same or opposite when compared to the RVs. All 
analysis performed in this paper uses a degree of error of π/2. B) A cell contraction and relaxation plot 
using categorical variables (contractions =1; rest = 0; relaxations = -1).The duration of a complete 
occurrence is measured by the number of time intervals in between the first time interval that exhibits 
contraction and the last time interval that exhibits relaxation prior to the resting phase. The frequency is 
defined as the number of complete occurrences per second. This value is derived by taking the inverse of 
the time difference between the first time interval of a complete occurrence and the first time interval of 
the subsequent complete occurrence. However, it should be noted that if there are n complete occurrence 
within a grid, only n-1 frequencies can be calculated. The frequency of the last complete occurrence 
cannot be calculated as the start of the subsequent occurrence is unknown. 
  
2.4 Principal component analysis  
2.4.1 Motivation 
 Solely looking at change in the magnitude of vectors has limitations in characterizing the 
contractile behavior of hPSC-CMs. One of the main shortcomings is that multiple phases of the 
cardiomyocyte contraction can embedded within a single peak in the average vector 
displacement trace. This exact scenario was seen when a monolayer of hESC-CMs was exposed 
to isoproterenol, a β-adrenergic agonist (Figure 2.1B). Upon the administration of 10 nM of 
isoproterenol, one of the corresponding peaks in the normalized displacement (change in 
magnitude of vectors) had multiple phases within it.
35
 This issue was resolved by using the 
aforementioned post-processing analysis in Section 2.3, which leveraged the change in vector 
orientation to correctly categorize each data point into one of three states: contraction, relaxation, 
or resting phase. However using categorical variables combined with user-dependent thresholds, 
noise and degree of error, there is a possibility of oversimplifying and distorting the original 
signal, resulting in the abnormal contractile behavior of hPSC-CMs being overlooked. Hence, 
additional post optical flow processing techniques were explored.  
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2.4.3 PCA background 
 Principal component analysis (PCA) is a statistical technique that can reduce the 
dimensionality of data sets through the generation of principal components. Each principal 
component is a linear combination of the data set’s variables that accounts for the variance 
within the data. The first principal component has the maximum variance, while subsequent 
principal components are uncorrelated to previous components and attempt to account for 
remaining variation.
36
 PCA can be achieved through the eigen-decomposition of the covariance 
matrix.
37
   Assuming the data (D, which is comprised of a MxN matrix) is centered, the 
covariance matrix C can be calculated (Eq. 4): 
     𝐶 =  
𝐷𝐷𝑇
𝑁−1
    (4) 
Once calculated, the eigen-decompostion entails the calculation of the eigenvalues, λi, and 
eigenvectors, vi, in which the following needs to be satisfied (Eq. 5)  
     𝐶𝑉𝑖 = 𝜆𝑖𝑣𝑖    (5) 
This can be further expressed in a matrix form, where V is the matrix of eigenvectors (Eq. 6): 
       𝐶𝑉 = 𝑉𝛬    (6) 
in which Λ represents the diagonal matrix of eigenvalues (Eq. 7) 
    𝛬 =  (
𝜆1 0 0 ⋯
0 𝜆2 0 ⋯
𝑥 𝑥 ⋱ 𝑥
⋯ ⋯ 0 𝜆𝑁
)   (7)  
We can then re-write Eq. 3 as following (Eq. 8) where V
T 
is equal to V
-1
 as C is symmetric. 
     𝐶 = 𝑉𝛬𝑉𝑇    (8) 
To calculate the principal components from this, we can set up our projection matrix, P (Eq. 9). 
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     𝑃 =  (
𝑣1
𝑇
𝑣2
𝑇
⋮
𝑣𝑁−1
𝑇
)    (9) 
The principal components will then be the multiplication of P
T
 to the original data set, in which 
the corresponding values of k
th
 (k < N) principal component will be the k
th
 row of the multiplied 
matrix.      
 
2.4.4 Implementation of PCA to generated vectors 
 The issue described in Section 2.4.2. was corrected through the application of PCA on the 
vectors generated from the optical flow algorithm. This implementation consisted of two primary 
steps, in which PCA was used initially for spatial analysis of the images. The vectors 
representing each pixel were first decoupled into their corresponding x-and y-axis components. 
PCA was then specifically applied to a matrix that consisted of these components over all frames 
of the video acquisition. The norms of the 1
st
 PCA value were then sorted in order of highest to 
lowest. The lowest number in the first quartile was then regarded as the mask threshold. As seen 
in Figure 2.3A, this mask segmented regions of interests that had large motion or changes in 
vector magnitude. This segmentation further increased the signal-to-noise ratio by reducing 
background noise from non-moving sections. With the regions of interest identified, another 
PCA was done on the x- and y-axis components with respect to time of the selected area for a 
temporal analysis. When the norm of the 1
st
 PCA values were plotted out, a contractile profile 
was generated in which the contraction and relaxation peaks of cardiac beats were automatically 
discerned without any user input (Figure 2.3B).  
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Figure32.3 Principal component analysis of optical flow vectors A) Brightfield videos of contracting 
cardiomyocytes are analyzed as images via optical flow. Vectors are generated to represent the motion of 
the cells. By performing the PCA analysis with respect to the spatial aspect of the videos, a segmentation 
mask is generated that indicates areas of motion. B) After segmenting regions of interest with the mask, 
PCA is performed with respect to the temporal aspect of the video. A contractile plot is generated in 
which the contraction and relaxation phases were automatically discerned (contraction phase indicated in 
red and positive PCA values and relaxation phase indicated in blue and negative PCA values). 
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2.5 Summary 
In our collective platform, a vector-based strategy using optical flow, was chosen as 
we have demonstrated that the directional component of a vector can be crucial in the analysis 
of cardiomyocyte motion. When looking at just the magnitude of pixel differences or vector 
displacement, a contractile beat is assumed to be represented by two distinct peaks (one 
representing the contraction phase and one representing relaxation).
26,28
 As mentioned 
previously, the ability to discern between the two phases can be achieved if a resting phase is 
present. However, if the beating frequency of the cells is increased, multiple phases can be 
embedded into one singular peak as we have shown (Figure 2.1B).
35
 Thus, methods that 
analyze both the magnitude and directional components of vectors should provide more 
detailed information. The described method of optical flow paired with PCA analysis is able 
to achieve this in an automated fashion, while requiring minimal equipment. Finally this 
brightfield method is applicable to longitudinal studies and various experimental designs, 
ranging from monolayers to 3D cultures (Chapter 6).  
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CHAPTER 3: Biomimetic materials for maturation of hPSC-CMs 
3.1 Introduction 
 Regardless of methodology to quantify human pluripotent stem cell-derived 
cardiomyocytes (hPSC-CMs), there is a concern that the immaturity of hPSC-CMs will lead to 
less-than-perfect predictability of a compound’s cardiotoxicity. hPSC-CMs exhibit fetal-like 
phenotypes, ranging from their gene expression to electrophysiological properties to cell 
morphology (e.g. lack of T-tubules).
8,9,38–42
 Such differences in phenotype have already resulted 
in disparate effects of cardioactive compounds when comparing in vitro data to those of in vivo. 
For example, studies have shown that hPSC-CMs may elicit a minimal to non-existent response 
to certain positive inotropic compounds, such as beta-adrenergic agonists.
43,44
 
As a result, multiple strategies have been employed in hopes of maturing hPSC-CMs for 
improved detection of cardiotoxicity. Such techniques include electrical stimulation after cardiac 
differentiation, a tri-culture including fibroblasts and endothelial cells, or the forced expression 
of selective proteins.
45–48
   
 A simple and chemical-free approach for hPSC-CM maturation involves the alignment of 
cardiomyocytes to recapitulate the anisotropic nature of the extracellular matrix (ECM) of the 
native myocardium. The alignment of hPSC-CMs alone has been shown to align sarcomere 
structures, produce stronger contractile forces, and cause anisotropic action potential 
propagation.
20,49
 All these changes suggest aligned hPSC-CMs would become more 
physiologically relevant for drug screening purposes. It should be noted that while the ECM of 
the native myocardium as a whole possesses an anisotropic nature, there is variability in the 
spatial arrangement, topography, and fiber bundle thickness among the ECM components. As an 
example, collagen, one of the most abundant proteins in the ECM, self-assembles fibrils with 
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diameters on the scale of 20 nm – 1.2 μm. These fibrils continue to form fibers with thicknesses 
that are several orders of magnitude higher.
50
 While cells have been aligned on surfaces with 
patterns of anisotropic features, the majority of these fabricated topographies have a repetitive 
and relatively homogenous size range.
51–53
 These narrow ranges and low variability do not 
emulate the multi-scale topography of the ECM. Thus, the Khine lab has fabricated a biomimetic 
substrate with anisotropic multi-scale wrinkle features that attempts to mimic the vast 
topography of the ECM. This chapter explores the impact of these biomimetic substrates on 
hPSC-CM response to cardioactive compounds.  
 
3.2 Biomimetic wrinkled substrates 
 The Khine lab has previously developed a method to create biomimetic substrates with 
anisotropic multi-scale wrinkle features in a fast and robust manner.
54
 To fabricate these 
substrates, films of pre-stressed polyethylene (PE) were oxidized with a plasma machine to 
create a stiff surface layer. When the film was shrunk (90% in length) through the application of 
heat, the stiffness mismatch between the surface and the bulk of the material caused the film to 
buckle and create multi-scale wrinkles. To generate anisotropic wrinkles, two parallel ends of the 
film were constrained during the heating process as seen in Figure 3.1A. Upon shrinking, a 
hierarchy of features is formed with major depths and wavelengths along with minor depths and 
wavelengths, demonstrating the multi-scale nature of the topography (Figure 3.1B).
54
 The scale 
of these depths and wavelengths can be tuned with relative ease by controlling the exposure time 
in the plasma machine. Shrunk PE substrates that are plasma treated for 5 minutes have wrinkle 
ranges of 60 nm to 3 μm, similar to that of natural ECM fibrils. In addition, a 1:200 dilution of 
Matrigel was coated onto the substrates. Atomic force microscopy measurements indicated that 
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the protein coating necessary for cell adhesion did not obscure the features of the wrinkles 
(Figure 3.1C)  Human embryonic stem cells, aortic smooth muscle cells, and mouse embryonic 
fibroblasts have all been aligned on these substrates.
54
  
Figure43.1 Fabrication of  multi-scale anisotropic wrinkled substrates A) i) Pre-stressed polyethylene film 
is treated O2 plasma to create a stiff oxidized surface ii) The film is then constrained on opposite sides and 
shrunk. Due to stiffness mismatch between surface and the rest of the film, anisotropic wrinkles are 
formed with micro- and nano-scale topography. iii) The wrinkled film can then be cut into a desired 
shape. iv) The film is then mounted onto a glass cover slip and v) can be inserted into standard cell 
culture plates. B) Schematic of hierarchical features.  Micro- and nano-scale features are present and 
dependent on time of plasma treatment. C) Atomic force microscopy image of substrate that was plasma 
treated for 5 minutes. The image demonstrates the multiscale topography of the biomimetic wrinkles was 
retained upon Matrigel coating. The scan distance was 5 x 5 μm2. Adapted from Chen, A. et al. Shrink-
film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their 
cardiac derivatives. Adv. Mater. 23, 5785–91 (2011) with permission from John Wiley and Sons. 
 
3.3 Alignment of hPSC-CMs on wrinkled substrates 
 To evaluate the effect of the substrate’s multi-scale topography, human embryonic stem 
cell-derived cardiomyocytes (hESC-CMs) with both αMHC-mCherry-Rex-Blar and αMHC-
Puror -Rex-Neor constructs (courtesy of the Mercola lab) were seeded onto three types of 
substrates: 1) flat, 2) 8 µM lined (mask created via photolithography), and 3) wrinkled substrates 
(formed by method described in Section 3.2).
35,55
 The 8 µM lined substrates (8 µM width with 8 
µM gap in between) represented substrates with topographies that had a repetitive and relatively 
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homogenous size range. hESC-CMs were differentiated with a protocol developed by Laflamme 
et al.
56
 Unlike the study in Section 3.2, where cells were directly seeded onto the PE film, poly-
dimethylsiloxane (PDMS) stamps were first molded to capture the inverse features of the 
original PE film. Subsequently the original features were then transferred into poly-styrene (PS) 
substrates via hot-embossing with PDMS stamps. PS was the material of choice as standard cell 
culture apparatuses (e.g. tissue culture-treated well plates) use it for its bio-compatibility and 
optical clarity. To enhance protein adhesion and sterilize the surface, the substrates underwent 
UVO treatment for 8 minutes, prior to fibronectin coating. Finally cells were seeded onto the 
various substrates at a density of 5x10
5
 cells/mL.    
To quantify alignment, cells were stained for α-actinin, f-actin, and nuclei 24 hours after 
initial seeding as seen in Figure 3.2A. For analysis of f-actin stains, alignment was specifically 
defined as the percent of f-actin aligned to within ±15° to the direction parallel to the line or 
wrinkled patterns. To calculate this, images of labeled actin were filtered to estimate the image 
gradient at each pixel location using a Gaussian derivative (sigma=2pixels). The distribution of 
orientations was estimated by computing a histogram of gradient orientations where the 
contribution of each pixel was weighted by the gradient magnitude. These weights limited the 
contribution of pixels in low contrast regions of the image where the gradient orientation 
estimate was uncertain. The orientation histogram was computed for n=12 disjoint 300x300 pixel 
subwindows in each image.  The standard deviation is computed across the subwindows. For the 
hESC-CMs, 20 ± 2, 35 ± 0.5, and 42 ± 1% of the cells aligned on flat, line, and wrinkled 
substrates, respectively (Figure 3.2B, left panel). The alignment efficiency of hESC-CMs grown 
on the wrinkles was about 20% higher than those grown on the line. 
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The analysis of α-actinin stained images corresponded to the alignment and organization 
of sarcomeres. An algorithm developed by Bray et al. was used for ridge detection to determine 
the sarcomere structures in images.
57
  Based on the pseudo vectors produced by the algorithm, 
the orientational order parameter (OOP) was calculated.
20
  An OOP value of 0 represents a 
complete randomized organization, and a value of 1 represents a perfect organization of 
structures.  For the hESC-CMs, the OOPs were 0.06 + 0.01, 0.17 + 0.02, and 0.25 + 0.02 for 
cells aligned on flat, line, and wrinkled substrates, respectively (Figure 3.2B, right panel). The 
OOP of the hESC-CMs cultured on the wrinkled substrates is close to the OOP measured in 
primary rat ventricular cardiomyocytes (~0.45) cultured on anisotropic fibronectin patterns.
58
  
These results both indicate that wrinkled substrates aligned the cardiomyocytes more efficiently 
than the control substrates, flat and 8 µM lined. 
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Figure 3.2 Alignment of hESC-CMs on various substrates A) (top panel) Scanning electron microscope 
images of flat, line, and wrinkled substrates at 1000× magnification. (middle panel) Fluorescent images of 
f-actin of hESC-CMs aligned on various topographies. The images were taken at 20× magnification. 
(lower panel) Fluorescent images of α-actinin of hESC-CMs aligned on various topographies. The images 
were taken at 40× magnification. B) (left panel) Quantification of the f-actin alignment efficiency. Bar 
graph showed the percent f-actin alignment. (right panel) Quantification of the sarcomere alignment 
efficiency using orientation organization parameter. 
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3.4 Drug response of hPSC-CMs cultured on biomimetic wrinkles 
 While the wrinkled substrates demonstrated the best alignment of cardiomyocytes among 
the three substrates, the effects on hESC-CM response to cardioactive compounds were 
evaluated by screening E-4031, a hERG K
+ 
channel blocker, and isoproterenol, a β-adrenergic 
agonist. For all screens, drug compounds were added in a serial manner to achieve cumulative 
concentrations. E-4031 was tested at 0, 1, 3, 10, and 30 nM, while isoproterenol was tested at 0, 
0.1, 1, 10, and 100 nM. All cardoactive effects and changes in hESC-CM behavior were captured 
with brightfield microscopy and analyzed with the optical flow technique and post optical flow 
contraction (pOFC) analysis described in Section 2.3.1 and 2.3.2. Again, the pOFC was able to 
compute key contractile parameters: 1) duration of contractile duration, 2) beating frequency, 3) 
synchronicity of monolayer, 4) orientation (the sum of magnitude for all y-axis components and 
the sum of magnitude of all x-axis components), and 5) acceleration. Cardiac cells from all 
surfaces exhibited increased contractile duration when treated with 10 nm E-4031; however, only 
those grown on the wrinkles responded to 3 nm of E-4031 as indicated by reduction in the 
contractile orientation. The concentrations of 3 and 10 nm of E-4031 are comparable to the 
published IC50 in hERG channel assay (7 nm).
59,60
  
 Isoproterenol is a known chronotropic, dromotropic, and inotropic agent to cardiac cells. 
This drug was originally developed for treating asthma; however, arrhythmia is a known serious 
adverse effect.
61
 Three trials of isoproterenol were conducted in which each three cardiac cell 
ages were evaluated. Cells were around differentiation days 20, 40, and 60 for trials 1, 2, and 3, 
respectively. After administration of the drug compound, all cells exhibited increase in 
contractile frequency and acceleration on all surfaces regardless of cell ages (Figure 3.3, Table). 
The drug also affected the contractile duration (all three trials), synchronicity (all three trials), 
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and orientation (trial 2 and 3 only) of cells grown on the wrinkles; these differences were not 
evident in the flat and line substrates. While hESC-CMs demonstrated immature properties, 
providing these cells with topographical cues that are similar to those in the native heart might 
force the cells to behave as a more mature tissue. Therefore, a more evident contractile response 
to the drug treatment for those grown on the wrinkles can be quantified compared to the other 
two surfaces. 
 The topographical effects on CMs could also be inferred from these sets of experiments. 
Most of the contractile parameters were similar between cells grown on the flat and wrinkles at 
differentiation day 40 and 60. However, at differentiation day 20, the cells grown on the wrinkles 
were more responsive to the drug than those grown on both flat and line surfaces (Figure 3.3, 
bar graphs). Since isoproterenol is known for affecting calcium ion channels, these results could 
imply that the expression and development of ion channels of cells grown on the wrinkles might 
be more effective than those grown on the other surfaces in the earlier post differentiation period.  
24 
 
 
Figure53.3 Effects of isoproterenol (also known as isoprenaline and referred to as such in this figure) on 
cardiac cells growing on various topographies. Bar graphs summarized results from trial that evaluated 
the drug effects on cells at differentiation day 20. The table summarized the changes in contractile 
parameters between 0 and 100 nM isoprenaline in all trials. The values are the percent changes compared 
to the 0 nM condition. Green up arrow indicated an increase, gray horizontal arrow indicated no change, 
and red down arrow indicated a decrease in the values associated with the corresponding parameters. 
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3.5 Summary 
 Biomimetic substrates with anisotropic and multi-scale wrinkles can be fabricated from 
pre-stressed plastics with relative ease. These substrates induced better alignment in 
cardiomyocytes than the control substrates, flat and homogenously lined surfaces. The sensitive 
responses of cells seeded on the wrinkled surfaces in both the E-4031 and isoproterenol 
screening suggest that  the alignment of cardiomyocytes alone is not enough; instead, the multi-
scale topography  ranging from the micro- to nano-scale is crucial and may induce more mature 
ion channel development in cardiomyocytes. The use of these biomimetic substrates may be 
beneficial in the screening for cardiotoxicity as the cardiomyocytes may respond more similar to 
those found in the native myocardium. Unlike other techniques that aim to mature hPSC-CMs 
for more physiologically relevant phenotypes, the use of these substrates is chemical-free and is 
relatively inexpensive. The wrinkled features are not limited to PS and can be transferred into 
any material that can be hot-embossed or molded. These biomimetic substrates can be easily 
integrated with other methods to further address the fetal-like qualities of hPSC-CMs for drug 
screening purposes.   
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CHAPTER 4: Adaptation of wrinkled substrate for high-
throughput screens 
4.1 Introduction 
 A key criterion in whether a detection platform is implemented for the screening of 
cardiotoxicity is its suitability for medium to high-throughput use. Typically, target based or 
biochemical assays can achieve screens of 10,000 compounds per assay per day through 
automation and small volume formats. While using mammalian cell-based assays has more 
limitations, cardiotoxicity screening platforms that are commercially available and use hPSC-
CMs are already incorporating 96 to 1536 wells plate formats.
62
 In terms of the biomimetic 
substrates, the study in Chapter 3 Section 3.4 used the substrates and cells in a manner that was 
inefficient for throughput.  To form one confluent monolayer on the substrate (cut in the shape of 
a 15 mm circular glass coverslip), a density of 5x10
5
/mL was needed.  However, within the field 
of view for the microscope (10x objective on Nikon TE 300), less than 1% of the surface area 
(~0.59 mm
2
 of 353.25 mm
2
) was being recorded at a given time. Taking acquisitions of multiple 
locations across the substrate cannot be considered as multiple independent samples. Because the 
cardiomyocytes were in a confluent monolayer, they beat synchronously, were electrically 
linked, and must be treated as one sample. 
 While it is possible that the biomimetic substrates can be configured for the bottom of 96 
well or 384 well plate, concerns over the effects of evaporation and gas-exchange on cell 
behavior arise when lower-assay volumes are involved. 
63
 Thus, for the platform developed by 
the Khine lab, an alternative approach was taken to adapt the biomimetic substrates for high-
throughput use. To increase throughput, islands of cardiomyocytes with micron-range 
dimensions are selectively patterned onto a single surface, allowing for multiple independent 
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samples to be present within a substrate. In addition, without the need for a physical barrier (e.g. 
wall of a well), the islands can be placed within close proximity such that multiple samples can 
be captured within one video acquisition. Such acquisition would increase throughput by 
reducing overall processing time required by the optical flow. This chapter details the chemical 
approach that is taken to achieve this patterning and the corresponding characterization of 
formed islands.   
 
4.2 Micropatterning islands of cardiomyocytes 
4.2.1 Surface Modification  
 A popular approach to selectively pattern proteins onto surfaces is microcontact printing. 
The basis of this approach is to load an ‘ink’ (solution containing desired proteins to be 
transferred) onto the surface of an elastomeric stamp and then, apply the stamp face down onto 
final substrate with a select amount of force. If the substrate has a surface that is more 
energetically favorable than the surface of the stamp, the proteins will transfer in the areas where 
the stamp and substrate make contact.
64,65
 The surface energy of either the stamp or substrate can 
be modified to alter protein adsorption or transfer efficiency with techniques, such as plasma- or 
UV-treatment and fluorine based silanization.
64,66
  
 Microcontact printing was initially attempted to selectively pattern proteins on the 
wrinkled substrates. However, mixed results were achieved as the quality of the transfers was 
highly variable. One of the major issues was that wrinkled substrates have a heterogeneous 
surface with varying depths. Typically microcontact printing is performed on flat and 
homogenous surfaces, which allow the micro-features of the stamp to form a reversible seal. 
With the heterogeneous surfaces of the wrinkled substrates, the total surface area of contact 
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between the stamp and substrate was decreased, forming a weaker seal and allowing the stamp to 
slide. As a result, the resolution of the transfers was poor and in certain cases, the proteins would 
appear smeared. In addition, another factor in the variability of protein transfer was the amount 
of force applied to the stamp. While identical weights were used in each print, alignment of the 
center of the weights to that of the stamp was difficult. Thus, a disproportionate amount of force 
was applied to different areas of the stamp. This issue can be resolved, but would require the 
need for custom apparatuses. Therefore another method was south with the ability to pattern 
heterogeneous surfaces, reproducibility, and even distribution of protein among selected areas.  
 Ribeiro et al. demonstrated that using a process with 3-glycidoxypropyltrimethoxysilane 
(GPTMS), an organosilane, proteins necessary for cell adhesion can be 
covalently bonded onto surfaces, even those with high surface hydrophobicity (e.g. 
polydimethylsiloxane).
67
 Surfaces are activated by the bombardment of O2 plasma, which 
introduces polar functional groups that allows for linkage to the trimethoxysilane group of 
GPTMS.
68
 An advantage of the plasma treatment is that the activation across the surface is 
relatively uniform. In their study, Ribeiro et al. were able to culture neonatal mouse 
cardiomyocytes on laminin coated polydimethylsiloxane (PDMS) posts.
67
 
 We leveraged this GPTMS process and combined it with stencil lithography to create a 
method that is capable of patterning on heterogeneous surfaces with relative uniformity. As seen 
in Figure 4.1A, we first created a shadow mask using a CO2 laser cutter (VLS2.30). The mask 
was a polymer film (Grafix Arts, Frisket Film) with a removable single-sided adhesive that was 
left minimal residue. After laser cutting, the mask was applied to the surface of the substrate. For 
the demonstration of this select patterning using the GPTMS approach, we used PDMS 
substrates that were molded with the wrinkled features. The GPTMS process is not limited to 
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only PDMS, but it can be applied to glass, thermoplastics or anything that can be activated by O2 
plasma treatment. An advantage of using PDMS or a silicone based polymer is that the stiffness 
can be tuned by blending polymers or altering the ratio of base to curing agent. To ensure that 
the wrinkled features of the PDMS substrates were the same as the PS ones, the original PDMS 
stamps meant for hot-embossing were used. Typically molding PDMS from a PDMS template is 
challenging as the new silicone mixture may chemically bond with the template. To prevent this, 
the template was coated with 5% pluronic acid, a surfactant, prior to the molding step. The 
fidelity of the wrinkles were found to be similar to those of the PS substrates with no statistical 
difference among the roughness parameters calculate by a 3D laser scanning microscope 
(Keyence VK-X110). The mask and substrate were then O2 plasma treated (Plasma Etch PE-50) 
for 3 minutes. Afterwards, the mask was removed and the substrate was then incubated in a 
methanol solution of 20% GPTMS. Following methanol and deionized water washes, the 
substrate was dried with an air gun. To ensure dryness and sterilization, the substrates were 
autoclaved. Next, to prevent non-selective protein adsorption, non-functionalized areas were 
blocked with 5% pluronic acid for an hour (Pluronic F-127). Finally after phosphate buffer saline 
washes, the substrate was prepared for select protein coating.  
Aside from uniform protein deposition onto heterogeneous surfaces, this organosilane 
and stencil lithography approach provides other advantages that make it suitable for high 
through-put use. GPTMS, like many organosilanes, is stable at room temperature and in ambient 
environment unlike plasma treatment, which only has temporary effects. This stability gives it a 
shelf-life suitable for manufacturing and potential commercial needs. As seen in one of the steps, 
the GPTMS is thermally stable at the temperature range for autoclaving, allowing for convenient 
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sterilization. Finally as the process laser cuts the shadow masks, the dimensions of the micro-
islands can be changed with ease and without the need for a clean room. 
   
Figure64.1 Organosilane approach to selectively pattern cardiomyocytes A) A shadow mask is created by 
laser cutting a film with reversible and single-sided adhesive. B) After mask is applied to wrinkled 
surfaces, select areas are activated via O2 plasma treatment. C) Substrate is then incubated in an 
organosilane solution, 20% GPTMS in methanol. 4) Afterwards, substrate is autoclaved for sterilization. 
5) A surfactant, Plurnoic F-127, is used to block for potential non-selective protein adsorption. 6) 
Substrate is then coated with proteins for cell adhesion.  
 
4.2.2 Characterization of Patterns 
 Prior to coating ECM proteins and seeding cardiomyocytes on the wrinkled substrates, 
we conducted a feasibility test with tetramethylrhodamine isothiocyanate (TRITC)-conjugated 
streptavidin (λexcitation = 550 nm, λemission = 570 nm) as a model protein to demonstrate covalent 
attachment. As seen in Figure 4.2A (left panel), we first designed a mask with a square array of 
81 total islands. Each island was a square with 500 µM sides and was 500 µM apart from all 
neighboring islands.  Following the GPTS treatment as described in the previous section with the 
square array mask, a flat PDMS substrate was incubated with 10 µg/mL of streptavidin-TRITC 
for an hour at room temperature. When we imaged the substrates with an upright epifluorescence 
microscope (Olympus BX-53), we were able to affirm that arrays of proteins patterned as 
31 
 
squares were present. In Figure 4.2A (right panel), we do see that the edges of the squares were 
cragged and this could be attributed to the quality of laser cutting the frisket film. If perfectly 
smoothed lines are desired, a precise shadow mask can be machined from rigid materials such as 
metal; however the trade-off is that machining would be more expensive with a greater 
turnaround time for mask adjustments. Once it was established that proteins patterns could be 
deposited on flat surfaces, we repeated the process on the heterogeneous wrinkled substrates. 
From the images as seen in Figure 4.2B, we again patterned down proteins in a square array 
format. In Figure 4.2C, we see that the anisotropic features were preserved as they were 
identifiable.  
 
Figure74.2 Characterization of organosilane approach with streptavidin-TRITC. A) Shadow mask was 
designed with 81 islands with features of 500 µm x 500 µm with a 500 µm gap in between islands. 
Streptavidin-TRITC was used as a model protein to show deterministic patterning on flat PDMS surfaces. 
B) Organosilane treatment was then applied to heterogeneous surfaces, anisotropic wrinkled substrate. 
Fluorescent image of square array overlaid on original brightfield image. Image was taken with a 4X 
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objective. C) Fluorescent image (taken with a 10X objective) of an individual island showed that wrinkled 
features were still preserved after protein coating. 
 
4.2.3 Cell seeding and island independency 
 After the proof-of-concept on both homogeneous and heterogeneous surfaces, we plated 
stem cell-derived cardiomyocytes (stem cell line: hES2-7E) onto a PDMS substrate that had both 
flat and wrinkled surfaces. This PDMS substrate was designed to fit into a well of a 4 chamber 
slide (surface area of 1.7 mm
2
 per well). Substrates were seeded at a density of 4.2x10
5
 cell/mL. 
The substrates prior to seeding were coated with Matrigel diluted at a 1:200 ratio. As seen in 
Figure 4.3A, the cardiomyocytes plated as islands and retained their square shape. To ensure 
that the anisotropic wrinkles did have an effect on cardiomyocytes and their contractility, we 
captured brightfield videos of the human embryonic stem cell-derived cardiomyocytes (hESC-
CMs) contracting and measured the directionality of the vectors generated from the optical flow 
analysis as described in Chapter 2. In Figure 4.3C, the islands plated on the flat surface had a 
random orientation in the directionality of vectors, indicating no preference. However, the micro-
islands formed on the wrinkled surfaces had a much stronger preference for the x-axis, which is 
parallel to the anisotropic wrinkles. To quantify this, we again used the orientation parameter 
X/Y ratio, which is the ratio between the sum of x-axis components’ magnitudes and the sum of 
all y-axis components’ magnitude. A ratio of 1 would indicate that the directionality of the 
contraction was random and had no preference. A ratio larger than1 would suggest the islands 
have a preference in contracting along the x-axis. Based on this, the islands cultured on the 
wrinkled surface (n = 6) had a larger X/Y ratio (1.36 + 0.11) than the ratio (1.10 + 0.16) of those 
cultured on the flat surfaces (n = 4), indicating a stronger preference to contract within the 
direction of the x-axis.  
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 Another critical component of using the biomimetic substrates for high-throughput is that 
the formed islands of cardiomyocytes are truly independent samples. If the islands were 
independent from its neighbors, the contractile behaviors would be all different along with an 
asynchronous beating.  As seen in Figure 4.3B, when we examined a video of 4 neighboring 
islands (taken with a 4X objective on the Olympus IX83 microscope), the PCA contractile plots 
indicated very distinct contractile patterns. For example, the island in the top left of the image 
beat at a frequency that is approximately 3-fold lower than that of the island in the top right. In 
addition, based on the amplitude of the contractile plots, the contractility of the top left island 
was over two-fold less than that of the island in the top right. These results preliminarily show 
that we can leverage an organosilane treatment and stencil lithography to selectively pattern 
cardiomyocytes and increase the number of independent samples within a single substrate. 
 
Figure84.3 Evaluation of patterned islands’ contractility. A) hESC-CMs were selectively patterned onto 
the anisotropic wrinkled PDMS substrate in a square array manner. B) PCA analysis indicated that each 
island has a unique contractile pattern that is independent of its neighbors. C) Islands of hESC-CMs 
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formed on the wrinkled substrates (n = 4) were compared to those formed on flat surfaces by examining 
the X/Y parameter. The X/Y parameter is the ratio between the sum of x-axis components’ magnitude and 
the sum of all y-axis components’ magnitude. A ratio of 1 would indicate that the directionality of the 
contraction was random and had no preference. A ratio larger than1 would suggest the islands have a 
preference in contracting along the x-axis.  
  
4.3 Summary 
 In this chapter, we present a method to adapt the biomimetic wrinkled substrates for high-
throughput use. The capability to do so is essential in the commercial viability of these substrates 
as various commercial platforms have already demonstrated their capacity for throughput. The 
goal of our method was to pattern multiple islands of cardiomyocytes onto a single wrinkled 
substrate. Instead of physically transferring the proteins onto the surface (e.g. microcontact 
printing), we used an approach that combines organosilane treatment and stencil lithography. 
This combined method provides the advantage of reproducibly patterning onto heterogeneous 
surfaces with relative uniform deposition. In addition, by using a laser cutter, shadow marks can 
be altered and fabricated in short periods of time. We demonstrated that hESC-CMs can be 
controllably seeded in a square array format with this approach. Each of the islands had 
independent contractile behavior and the ability of the anisotropic features to align cells was 
preserved as the hESC-CMs seeded on the wrinkled substrates had a preference to contract in the 
direction parallel to the features. Besides increasing the number of independent samples, videos 
of the contracting islands were taken at a lower magnification such that four islands appeared 
within one view. By doing so, throughput is increased by reducing the computational resources 
and time to analyze the contractility of each island of cardiomyocytes. While we showed that the 
biomimetic substrates can be feasibly adapted for high-through put use, the method still needs to 
be optimized and further characterized for commercial use. In particular, the optimal ratio of 
seeding density to the surface area of each island needs to be determined for consistent formation 
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of monolayers. A potential concern with having multiple islands of cardiomyocytes on a single 
substrate is paracrine signaling (e.g. release of growth factors) between the islands in response to 
exposure of a drug compound. Such an issue can be mitigated by measuring cardiomyocyte 
response in a timely manner. For example, functional measurements of cardiomyocyte response 
during the drug screens described in Chapter 5 Section 5 were captured in 5 minute intervals. 
Paracrine communication can be estimated to take place on a time scale of 10-30 minutes. If 
longitudinal studies are desired, the formation of factor gradients can be minimized by placing 
the islands in a microfluidic platform with designed flow. We have demonstrated that these 
islands can be patterned and then encased in a fluidic platform.
69
 Finally, some other aspects of 
the organosilane and stencil lithography method that need to be explored include choice of 
protein for cell adhesion, substrate stiffness, and geometry of cardiomyocyte islands.    
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CHAPTER 5: Application of supervised machine learning 
5.1 Introduction 
Various screening platforms have emerged in recent years to address the need for more 
accurate and faster pre-clinical detection methods of drug-induced cardiotoxicity. A majority of 
these platforms have begun to utilize human pluripotent stem cell-derived cardiomyocytes 
(hPSC-CMs). Aside from the commonality of using hPSC-CMs, these screening platforms 
greatly vary in their setup. These systems can drastically differ in their methodology of 
quantifying changes in hPSC-CMs exposed to cardioactive compounds. Some systems examine 
the electrophysiological properties while others observe the calcium transients or directly 
measure the force being generated by hPSC-CMs.
16,30,46,70–74
 The nature of this outputted data 
becomes high-dimensional especially when multiple experimental conditions are present or a 
multiplex system is used.
29,75
 Traditional approaches of examining a few pre-determined 
parameters independently of one another may not adequately summarize and reflect cardioactive 
effects of a compound administered to hPSC-CMs. There is a possibility that the information that 
separates the behavior of normal hPSC-CMs from those exposed to the cardioactive compound is 
only present in disregarded parameters or a combinatorial form of examined parameters. 
Furthermore, as these platforms are designed for high-throughput screens, the analysis needs to 
be automated yet still provide comprehensive results. 
Rather, holistic approaches must be developed to optimize the utility of datasets 
generated from screening platforms. Machine learning offers a possible solution as it can 
evaluate multiple parameters simultaneously without a priori knowledge; therefore, it can 
discover unexpected relationships to potentially yield better detection. In this chapter, we 
demonstrate the application of machine learning to the data generated from two platforms that 
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vary in their methodology of quantifying changes in hPSC-CMs. Collectively, we show that 
machine learning can determine whether a compound is cardioactive, predict the compound’s 
mechanistic action based on a drug classification model, and provide drug response relationships 
between compounds. Such information would assist in streamlining the drug discovery pipeline, 
allowing for the rapid identification of select compounds for more in-depth follow up assays. In 
addition, this information coupled with knowledge of predicted class can guide scientists to 
efficiently and selectively screen for specific drug-to-drug interactions that prompt cardiotoxicity 
(e.g. disruption of Ca
2+
 handling when sofosbuvir and amiodarone are combined) instead of a 
brute force approach.
76
 Finally, machine learning is able to provide all of this information in an 
automated manner, which would be ideal for any high-throughput system.  
 
5.2 Binary SVM Background 
Support vector machine (SVM) is a form of supervised machine learning that can be used 
for classification purposes. SVM classifies data points into two groups by creating a decision 
boundary that separates the groups. In the example of Figure 5.1, where the goal is to separate 
the red x’s from the green circles, multiple lines can be drawn to complete this task. SVM is able 
to address this issue by choosing the line that maximizes the separation or margin between the 
two classes. This task is accomplished by finding the greatest distance between the nearest points 
in each class. These nearest points are referred to as the support vectors. The determination of the 
optimal separation line or hyperplane is solely dependent on the support vectors, a subset of all 
present data.
77,78
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Figure95.1 Classification with support vector machines. If the given task is to classify or separate the red 
X’s from the green circles, this can be achieved with a line as seen in left panel. However, this line is one 
of multiple lines can be drawn. SVM determines the optimal by maximizing the margin between the 
support vectors. That line is referred to as the hyperplane or decision boundary. The support vectors 
represent the data points that are located on the margin. In the right panel, the line separating the two 
groups appears to achieve the largest margin possible, making it the hyperplane. If a new unknown data 
point were to be classified and was on the right of the hyperplane, it would be labeled a green circle (it 
would be labeled a red X if the point was to the left of the hyperplane). 
In the example above, the classes could be separated with a linear hyperplane. However, this 
is not the circumstance with a lot of data, especially biological data. In Figure 5.2, it is apparent 
that a linear line cannot separate the green circles from the red x’s. The optimal line of separation 
is rather a polynomial line. SVM or a linear separation line can still be implemented if the data 
was mapped from the input space into a vector space (possibly higher-dimensions) with a 
function φ. However if the vector space is high-dimensional, representing the transformed data 
can be computationally consuming. Thus, the kernel trick is utilized. Instead of mapping all the 
data points into the higher-dimensional vector space, a similarity measure is calculated in the 
higher-dimensional space. In SVM, this similarity measure is simply the dot product of the 
transformed vectors in the higher-dimensional space. In the example of two dimensional data 
(x,z ∈ X) and an existing mapping function to N-dimensional space  
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(φ: X  ℜN), the inner product would be represented as 〈φ(x), φ(z)〉. There exists a kernel 
functions (K) such that K(x,z) = 〈φ(x), φ(z)〉. This kernel function is used in the calculation of 
the optimal hyperplane and allows for non-linear SVM classification.
79,80
  
 
Figure105.2 Non-linearly separable data and SVM. (Left panel) a linear separation cannot be used to 
separate the green circles from the red X’s, a linear separation line cannot be used. (Middle panel) Instead 
separation of the two classes can be achieved if a polynomial line or non-linear function was used. (Right 
Panel) To be able to utilize SVM, the current input space can be transformed with a function φ into a new 
feature space in which linear separation is viable. 
In scenarios where a hyperplane cannot be perfectly drawn while using either linear or non-
linear SVM and data points are present within the margins, a soft margin method can be 
introduced with a non-negative slack variable (ξ) that represents the degree of misclassification. 
The algorithm will then penalize for the degree of non-zero ξ.  In the search for an optimal 
hyperplane, it will result in a trade-off between a large margin and a small penalty error.
81
  
 
5.3 Detection of drug-induced cardioactivity 
5.3.1 Rationale and experimental design 
Using binary SVM, we were able to create a singular quantitative index that described a 
compound’s level of cardioactivity through the analysis of brightfield videos. To evaluate the 
efficacy of our method that pairs brightfield imaging and machine learning, we compared it to a 
more traditional fluorescent-based intracellular calcium assay. With human induced pluripotent 
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stem cell-derived cardiomyocytes (iPS-CMs), we screened three cardioactive compounds with 
distinct, dissimilar effects: E-4031 (hERG K
+
 channel inhibitor), verapamil (L-type Ca
2+
 channel 
blocker), and blebbistatin (myosin-II inhibitor). The concentration range for each drug was 
selected based on the demonstrated window of cardioactive effects in previous studies.
17
 To the 
best of our knowledge, we reported for the first time the integration of brightfield imaging with 
machine learning on iPS-CMs to detect drug induced cardioactive effects, and demonstrate 
superior performance to fluorescence-based methods. 
 
5.3.2 Drug treatment and time-lapse imaging 
To screen the three cardioactive compounds, iPS-CMs were seeded into 8-chamber Lab-
Tek II chamber slides (Electron Microscopy Sciences) at a density of 150,000 cells/well. All 
cardiomyocytes were 40+ days post differentiation for the drug screens. Prior to expo- sure to 
drug compounds, three baseline measurements were made at time points 0, 30, and 60 minutes, 
which represented a baseline or healthy iPS-CM contractile behavior. Drugs were serially added 
to the wells, waiting 20 minutes after addition before taking measurement. RPMI/B-27 was used 
as placebo. At each time point, videos of contracting cardiomyocytes were acquired with an 
Olympus IX83 (Olympus) inverted scope equipped with an ORCA-R2 color charge-coupled 
(Hamamatsu) camera and MetaMorph soſtware (Molecular Devices). To control for temperature 
and pH, an incubation system (model ZILCS) consisting of a stage top incubator, temperature 
controller, and gas flowmeter (Tokai Hit) was used with 5% CO2. Both fluorescent and 
brightfield acquisitions were taken for approximately 17.5 seconds at 15.6 fps at a resolution of 
672 × 512 or at 8.6 fps at a resolution of 1392 × 1040 (subsequently downsized to a resolution of 
672 × 512 via bilinear interpolation) and saved as a TIFF stack. To address variation among cell 
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populations within the same sample, stage locations were recorded prior to any acquisitions to 
ensure that the same cells among a sample were imaged. 
 
5.3.3 Fluorescent-based intracellular calcium assay 
For the fluorescence-based method, we utilized an iPS cell line transduced with a 
genetically encoded fluorescent calcium indicator, GCaMP6 (WTC11-AAV-CAG-GCaMP6; 
provided by Dr. Bruce Conklin of the Gladstone Institute of Cardiovascular Research). This 
method is similar to those found in industry for the high-throughput screening of drug-induced 
cardiotoxicity.
82–84
 In order to quantify the calcium transients, a 240 by 240 pixels region of 
interest (ROI) was selected for each video taken with the fluorescent channel (Figure 5.3C). The 
average intensity value within the ROI for each frame was measured and imported into 
MATLAB (MathWorks). An automated code was written to identify the start and the peak of 
each contraction. However, the raw GCaMP6 signal acquired over time showed a rapid decay 
due to photobleaching (Figure 5.3D). The photobleaching artifact was eliminated by fitting an n-
th (n  = 2-10) order polynomial curve to the baseline of the signal, defined as the starting point of 
the calcium transient, and then normalizing the raw signal by the baseline value (Figure 5.3E). 
In addition, the starting points were normalized to zero using linear interpolation. From this data, 
we calculated the beating rate and the calcium transient duration 90% (CTD90), defined as the 
duration of the fluorescent signal that was 90% below the peak amplitude of the transient 
(Figure 5.3F).  
In addition to the rapid photobleaching over a single acquisition time frame, we noted 
that the GCaMP6 signal also experienced a smaller photobleaching effect over multiple 
acquisitions. This loss of signal intensity caused artificial decreases in CTD90; this was corrected 
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by normalizing CTD90 with the amplitude of the calcium transient signal (Figure 5.3G). This 
corrected value is referred to as the Shape Ratio 90 (SR90), and serves as one of the two 
parameters analyzed for the GCaMP6 method with the other parameter being beating frequency. 
This effect was independent of time between acquisitions. A compound was deemed to be 
cardioactive if any of the concentrations were different from the control with statistical 
significance in either of the two parameters. Statistical significance was measured with one-way 
repeated measure ANOVA. If a significant p-value (p-value < 0.05) was obtained from the 
repeated-measures ANOVA, we proceeded with Dunnett’s test to determine which concentration 
differed from our baseline measurements. Differences with p-values less than 0.05 were 
considered statistically significant. All reported values in Section 5.3 are in the format of mean + 
S.E.M. All reported sample sizes (n) refer to independent wells of chamber slides (biological 
replicates). 
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Figure115.3 Data acquisition and analysis for GCaMP6 and brightfield signal. A) For the brightfield 
method, images were processed by an optical flow algorithm to generate vectors that represent the 
motion of the iPS-CMs. The blue vector arrows represented the average motion of 20 × 20 pixel 
regions, while the red vector arrows represented 50 × 50 pixel regions. The convergence of the vector 
arrows toward a center visually represented an iPS-CM cluster in the contraction phase. B) Based on 
the vectors, a contractile profile was derived from the 1
st
 PCA of the norm of the x- and y-vectors. 
Positive PCA values indicate contraction phase, while negative values signify the relaxation phase. C) 
GFP signal produced by the contraction of cardiomyocytes derived from GCaMP6 iPS cells. D) 
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GCaMP6 signal recorded over time for 3 sequential acquisitions at baseline. The signals showed a 
rapid photobleaching effect within the first 5 seconds, but also showed a photobleaching effect 
between the different acquisitions. E) The starting points and peaks of the calcium transients were 
identified using the detrended GCaMP6 signal. F) A graphical explanation of CTD90. The SR90 is 
defined as the ratio of CTD90 to the amplitude of a given calcium transient. G) A longitudinal 
experiment showed an artificial decrease in CTD90 due to photobleaching. This was corrected by 
normalizing by the amplitude in SR90. 
 
5.3.4 Quantification of brightfield imaging with binary SVM 
In the brightfield analysis, optical flow, as described in Chapter 2 Section 2.3.1, was used 
to generate motion vectors representing iPS-CM contractions (Figure 5.3A). Using principal 
component analysis (PCA) as seen in Chapter 2 Section 2.4.4, we summarized these motion 
vectors into a contractile profile that contained distinct peaks that represent the contraction 
(positive PCA values) and relaxation (negative PCA values) phases (Figure 5.3B). A total of 12 
parameters or attributes describing the contraction and relaxation phases of the contractile plots 
were derived as seen in Table 1 and inputted for the machine learning.  
Examined Parameters 
1. Contraction duration 7. 
Time from max peak to baseline of 
contraction 
2. Relaxation duration 8. 
Time from max peak to baseline of 
relaxation 
3. Contraction amplitude 9. Area under the curve of contraction 
4. Relaxation amplitude 10. Area under the curve of relaxation 
5. 
Time from baseline to max peak of 
contraction 
11. Frequency 
6. 
Time from baseline to max peak of 
relaxation 
12. Total duration 
 
Table11.1 Parameters derived from PCA contractile plots 
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For the machine learning algorithm, a machine is trained with data to create an optimal 
model with generalizability. SVM classifies the data points into two groups (e.g. normal and 
abnormal cardiomyocyte behavior) by creating a decision boundary that separates the two 
groups. The model is evaluated by classifying unseen or withheld data. This evaluation yields an 
accuracy value (SVM accuracy) that reflects the effectiveness of the model. The percentage 
accuracy represents the ability to identify an effect (e.g. 98% represents out of 100 samples, the 
machine can correctly classify 98 of the instances). In the absence of cardioactive compounds, 
we would expect the accuracy of the machine learning to be random and therefore generate a 
SVM accuracy of approximately 50%.  
Each of the cardiomyocyte contractions was then regarded as an individual sample for the 
machine learning (ML) analysis. Support vector machine (SVM), a classifying ML algorithm, 
was implemented to discern between normal and abnormal cardiomyocyte contractile profiles. 
As most biological data do not have linear trends, a non-linear kernel, radial basis function, was 
chosen for SVM. The classification between the contractions of the baseline measurements and 
those of a given drug concentration was accomplished by randomly separating the data into a 
training set and a test set. The data in the test set was withheld from the training process and only 
used to evaluate the model. The two sets were formed by first randomly grouping one third of the 
wells and the corresponding contractions of that drug condition into the test set. To ensure that 
the test set has equal number of baseline and drug samples, the baseline measurements for one 
ninth of the wells were randomly allocated for the test set. The reason was that the number of 
baseline measurements for each well outnumbered each drug condition of that corresponding 
well three to one. The rest of the wells and respective contractions were used as the training set. 
Within the training set, a 5-fold cross validation was performed to optimize the parameters for 
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the generated SVM model. The optimized SVM model was then used to classify the test set. The 
SVM accuracy of the model was calculated by the ratio of correct classifications to the total 
classifications for the test set. To account for potential sampling bias, this process was performed 
50 times and the reported SVM accuracy was the average of all the runs. With this process 
repeating numerous times and having random allocation each time for the test and training sets, 
the size of each respective set varied from run to run. For the baseline measurements, each well 
had approximately 9 contractions per video acquisition. With these numbers of contractions, the 
training set used for the SVM classifier had at least 200 samples.  
 
5.3.5 Longitudinal and placebo studies 
 To ensure that the experimental setup (i.e. stage top incubator), time, and other external 
factors did not significantly impact the behavior of iPS-CMs, a longitudinal experiment was 
performed. iPS-CMs were recorded with both the GCaMP6 method and brightfield method for a 
total of 150 minutes at intervals of 30 minutes. In the analysis of the GCaMP6 signals, there were 
no changes in the beating rate and SR90, indicating stability in the iPS-CM behavior during the 
length of the experiment. For the brightfield method, the SVM classification was performed by 
grouping the first three measurements (0, 30 and 60 minutes) as the baseline control in a similar 
fashion to the GCaMP6 analysis. The baseline control was then compared to the 90, 120 and 
150 minute time points. Corresponding SVM accuracies of 48.64 ± 1.51, 48.22 ± 1.57, and 
49.67 ± 1.41% were calculated (Figure 5.4A), which are consistent with no longitudinal effect. 
 The purpose of the placebo experiment was to evaluate the drug delivery process and 
serve as the vehicle controls. In each placebo condition, 10 μL of RPMI/B-27 media, the vehicle 
for drug treatment, was added to the iPS-CMs, for a total of four placebo deliveries. Analysis 
with the GCaMP6 method indicated no change in beating rate and SR90 values when compared 
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to the three baseline measurements taken prior to the placebo treatments. In the brightfield 
method, the SVM accuracies were 48.75 ± 1.01, 46.86 ± 1.19, 50.40 ± 0.98, and 55.67 ± 1.03% 
respectively for each of the placebo treatments (Figure 5.4B), again consistent with no effect. 
The data from both the longitudinal and placebo studies suggested only small and negligible, 
variations in iPS-CM behavior over time. Thus, the drug delivery process had no significant 
impact on the behavior of iPS-CMs. 
 
Figure125.4 Analysis of control experiments: longitudinal and placebo experiment. A) In the 
longitudinal experiment, behavior of iPS-CMs was monitored for an extended period of 150 minutes at 
30 minute intervals after baseline measurements. When the machine was tasked of classifying between 
the first and last half of the timepoints, the SVM accuracies were approximately 50% as expected 
(n = 13). B) To ensure the drug delivery process had no effects on iPS-CMs, at each placebo condition, 
10 μL of media was added to the previous tested condition. The average SVM accuracy of all four 
placebo conditions was 50.42%, similar to that of the longitudinal experiments (n = 18). C) 
Representative traces of the contractile profile from the brightfield analysis show no differences 
among tested conditions. 
 
5.3.6 Screen of cardioactive compounds 
E-4031 is a known antiarrhythmic drug that blocks the human Ether-à-go-go-Related 
(hERG) K
+
 channel and subsequently prolongs the QT interval.
85,86
 The drug compound was 
administered to the iPS-CMs at an increasing concentration of 1, 3, 5, 10 and 30 nM. E-4031 
induces QT prolongation, which was clearly seen in the contractile profiles generated from the 
brightfield images (Figure 5.5A). At the 10 nM condition, extension of the relaxation phase was 
seen, consistent with the inhibition of the hERG K
+
 channel that contributes to the rapid 
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repolarization of the cardiomyocytes. The lengthening of the relaxation phase became more 
evident and dramatic at the next treatment level, 30 nM. 
For the brightfield method, the SVM accuracies for concentration levels of 1 nM, 3 nM, 
and 5 nM (47.38 ± 0.64, 50.45 ± 1.05, and 49.19 ± 1.49%) were similar to the baseline SVM 
accuracies (48.84%) (Figure 5.5B). At the 10 nM concentration, the SVM was able to attain an 
accuracy of 79.82 ± 0.77%. The SVM accuracy continued to increase to 83.55 ± 1.08% at 30 nM 
concentration. At the higher concentrations (10 and 30 nM), noticeably higher SVM accuracy 
values were achieved, suggesting drug-induced effects. These observations were corroborated by 
the GCaMP6 data, which showed statistical significance among the parameters at 10 and 30 nM. 
With the GCaMP6 method, a change in beating rate was detected only at 30 nM with a 6.38% 
decrease (Figure 5.5C). The SR90 increased by 10.73% and 21.51% for 10 nM and 30 nM 
respectively (Figure 5.5D), which were statistically different from baseline. This separation in 
accuracy values highlights the utility and applicability of machine learning for drug screening 
purposes. 
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Figure135.5 Analysis of E-4031, a hERG K
+
 channel blocker. A) Representative traces of the 
contractile profile from the brightfield analysis show a pronounced contraction elongation at the 
highest tested concentration (30 nM). B) At the concentrations of 1, 3, and 5 nM, the SVM accuracies 
were approximately 50%, similar to those of the control experiments. For the 10 and 30 nM 
concentrations, the SVM accuracies increased to 79.82 ± 0.77% and 83.55 ± 1.08% respectively. This 
increase among accuracies suggest the compound had a cardio-modulating effect on the cells at those 
given concentrations (n = 15). C) Using the GCaMP6 method, significant changes in the beating rate 
were seen at the 30 nM concentration (p = 0.0175). D) For the SR90 parameter, significant differences 
were detected at the 10 and 30 nM concentration (p = 0.0355 and p ≤ 10−4 respectively) (n = 15). 
*p < 0.05, ***p < 0.001. 
 
Verapamil was the second cardioactive compound to be screened. It is an L-type 
Ca
2+
 channel blocker that is used therapeutically to treat cardiac arrhythmia.
86,87
 The drug 
compound was administered at increasing concentrations of 1, 10, 50, and 100 nM. Verapamil 
causes QT shortening
88
, which was consistent with the observed decrease in the duration of the 
contractile profile, first seen at 10 nM (Figure 5.6A). At 50 and 100 nM, the shortening effect 
became more pronounced. In addition, the amplitude of the contractile profiles significantly 
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decreased, indicating a negative inotropic effect due to decreased levels of intracellular calcium. 
In the brightfield method, the 1 nM concentration level had a SVM accuracy value of 
64.52 ± 1.78% (Figure 5.6B). At the 10 nM level, the generated SVM models generated were 
able to achieve a SVM accuracy value that exceeded 90% (90.64 ± 1.49%). The SVM accuracy 
values continued to increase for the 50 nM and 100 nM concentration levels (94.32 ± 1.47 and 
96.39 ± 1.16% respectively). With the GCaMP6 method, the beating rate decreased by 32.93% 
and 56.39% for 50 and 100 nM, respectively (Figure 5.6C), which were statistically significant. 
A change in the SR90 value, a 45.42% increase, was statistically significant only at the highest 
concentration of 100 nM, (Figure 5.6D). 
Interestingly, at 10 nM of verapamil, a SVM accuracy of 90.64% was reported, indicating 
a change in cardiomyocyte behavior, while the lowest concentration level that had a significant 
change in the GCaMP6 data was at 50 nM. As verapamil inhibits the L-type Ca2+ channel, both 
the amplitude and duration of the calcium transient would be reduced. Thus, when normalizing 
by the amplitude to calculate SR90, the decrease in CTD90 could be masked by the decrease in 
amplitude. The shortened contractile profile and decrease in CTD90, may suggest that the effects 
of verapamil were masked at lower concentrations. If this is the case, the increases in SR90 values 
at higher concentrations indicate that the relative decrease in the amplitude is greater than the 
decrease in the duration of the calcium transient. 
The SR90 parameter is prone to inaccuracies in drug compounds that elicit similar and 
simultaneous changes in the amplitude and duration of calcium transients. However it is 
necessary as a means of normalization to counteract the photobleaching effect seen in the 
GCaMP6 method. Attempts to normalize the decay to the control experiments were not possible 
as the decay pattern among each sample of the longitudinal experiments greatly differed. Due to 
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unpredictability of the this decay, modeling the decreasing trend as linear or exponential 
functions dependent on the acquisition number was unsuccessful as well. This photobleaching 
effect is not unique to the GCaMP6 method, but rather present in most fluorescence-based 
techniques. Although there are ways to minimize photobleaching effects, there are considerable 
trade-offs. One method of adjustment is reducing the laser intensity; however, this reduces 
signal-to-noise ratio and does not remove the photobleaching effects altogether. A line-scan 
mode of acquisition can significantly reduce photobleaching, but this method eliminates wide 
field-of-view image acquisition, making it less suitable for high-throughput screening. These 
degradation in signals further highlight the advantage of using a brightfield method at it is not 
subject to this photobleaching effect and can be adapted for high–throughput, longitudinal 
studies on the same set of the iPS-CMs.  
 
Figure145.6 Analysis of verapamil, L-type Ca
2+
 channel blocker. A) Representative traces of the 
contractile profile from the brightfield analysis show the QT shortening effect begin at 10 nM and the 
negative inotropic effect at 50 nM. B) At 1 nM, the SVM accuracy was 64.52 ± 1.78%. At the 10, 50, and 
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100 nM concentrations, the SVM accuracies were all above 90%, strongly indicating verapamil’s cardio-
modulating effect. (n = 14). C) In the GCaMP6 method, significant changes were detected at the 50 and 
100 nM concentrations (p ≤ 10−4 and p ≤ 10−4). D) Looking at SR90, significant differences were only 
detected at the 100 nM (p = 8.78 × 10−4) (n = 14). ***p ≤ 0.001. 
 
Blebbistatin, a myosin-II inhibitor and a known excitation-contraction decoupler, was the 
final compound to be screened and was expected to have no changes in the GCaMP6 signal as 
the inhibition occurs downstream in the proteins that generate the force of contraction, and not 
intracellular calcium.
89
 The drug compound was administered at an increasing concentration of 
1, 10, 100, 500, and 1000 nM. The SVM accuracy values for the 1 nM and 10 nM concentration 
levels were near 50% (44.02 ± 1.45 and 47.38 ± 1.44% respectively) (Figure 5.7B). However, at 
100 nM, the SVM accuracy increased to 85.08 ± 1.49%. For both 500 and 1000 nM, SVM 
accuracy values increased to nearly 100% (99.67 ± 0.26 and 99.03 ± 0.57% respectively). 
Conversely, in the GCaMP6 method, there were no changes for any of the given concentrations 
(Figure 5.7C & D). 
As an excitation-contraction decoupler, blebbistatin induces a negative inotropic effect on 
the iPS-CMs. The expected negative inotropic effects were seen starting at 100 nM (Figure 
5.7A). At the highest concentration of 1000 nM, contraction and relaxation phases were still 
distinctly seen. However, the max amplitude of the contraction peak for the 1000 nM 
concentration was approximately 33-fold smaller than that of the baseline measurement (121.00 
PCA value compared 3976.42 PCA value). 
As seen above, the predictions of blebbistatin as a false negative in the GCaMP6 method 
were confirmed as the analysis showed there were no differences in any of the tested 
concentrations. However, in the brighfield method, a decrease in the amplitude of the contractile 
profile was seen starting at 100 nM. This experiment clearly demonstrates that methods based on 
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the electrophysiological profiles, such as patch clamping, fluorescence-based optics, and MEA, 
are prone to type II errors with drugs such as blebbistatin that decouple excitation and 
contraction of iPS-CM. Thus, it is crucial in future cardiotoxicity drug screening assays to have a 
component that monitors contraction and relaxation of the iPS-CMs. 
 
Figure155.7 Analysis of blebbistatin, a myosin-II inhibitor. A) Representative traces of the contractile 
profile from the brightfield method showed significant loss of contractility at higher concentrations. B) At 
1 and 10 nM the SVM accuracies were near 50%, suggesting minor to no changes in iPS-CMs. At 
100 nM, the accuracy increased to 85.08 ± 1.49%. For 500 and 1000 nM, the respective SVM accuracies 
further increased and were both near 100% (n = 11). As expected with the GCaMP6 method, blebbistatin 
resulted in a false negative with no changes in C) beating rate or D) SR90 at any of the tested 
concentrations (n = 11). 
In summary, through the monitoring of IPS-CMs exposed to three compounds with 
distinct cardioactive effects, we presented a screening method that combines brightfield 
microscopy and machine learning to enable the sensitive detection of changes in the contraction 
of human iPS-derived cardiomyocytes. This combined method was comparable to – and even 
superior to – fluorescence readouts. With binary SVM, a singular quantitative index was created. 
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This index or metric not only summarized the impact of 12 parameters of interest, but also 
examined any underlying relations or interactions among parameters. This index becomes 
valuable for high-throughput screening of drug-induced cardiotoxicity by highlighting 
compounds that have any cardioactive effect on the contractile behavior of cardiomyocytes. 
 
5.4 Multi-class SVM background  
Pertaining to multi-class SVM, there are generally two approaches: 1) consider all the data in a 
singular optimization problem and 2) decompose the task into a set of binary classifications. The 
former approach will be avoided as it will most likely be inefficient as in most cases no single 
mathematical function exists to separate all classes of real data sets.
90
 With the latter approach, 
two popular methods (one-against-all and one-against-one) exist. The one-against-all method has 
a binary classification for each class against all the other classes combined, as seen in Figure 5.8 
(Left Panel). A data point would only be classified as a certain class if and only if that class 
SVM’s accepted it while all the SVMs of other classes rejected it. As a result of this method, 
there exists regions in the feature space where a class cannot be defined. With the one-against-
one approach, a binary classification is performed for each pair of classes as seen in Figure 5.8 
(Right Panel). The simplest way to then perform a multi-class classification is to select the class 
that was chosen by the highest number of pair-wise SVMs. In summary, SVM is a powerful 
classification tool that is effective in high dimensional spaces, not bound to local minimums, and 
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memory efficient with selected use of training points (support vectors).
91
 
Figure165.8 Multi-class classification approaches. Multi-class classification can be broken down into a set 
of binary classifications. (Left panel) In the one-against-all approach, each class is classified against the 
rest of the classes combined. Upon this, a data point is only classified if one class accepts it and the others 
reject it. This methodology would yield feature spaces that are not accounted for. (Right panel) In the 
one-against-one approach, each class is classified with every other class in a pair-wise manner. While this 
method typically reduces the number of feature spaces that are not accounted for, it may be more resource 
intensive. 
 
5.5 Prediction of cardioactive compounds’ mechanistic actions 
5.5.1 Rationale and experimental design 
While capable of analyzing vectors generated from optical flow, binary SVM and other 
machine learning techniques can be readily applied to data of various screening methodologies. 
This flexibility was demonstrated by applying machine learning to the force measurements of 
human ventricular cardiac tissue strips (hvCTS) exposed to cardioactive compounds. hvCTSs are 
9 mm tissues that model cardiac muscle fiber. These measurements of hvCTS belonged to a 
database generated by Dr. Ron A. Li’s research group of Hong Kong University in conjunction 
with Novoheart. A unique aspect of these drug screens was that the hvCTSs were paced at four 
different frequencies. These measurements allowed a perspective on whether cardioactive 
compounds can influence force-frequency relationships and further highlighted machine 
learning’s ability to analyze a high dimensional datasets. Aside from determining if a compound 
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is cardioactive, we leveraged the machine learning to create drug classification model that can 
predict an unknown compound’s mechanistic action. In addition, the binary SVM approach was 
repurposed to explore drug response relationships between compounds. To accomplish these new 
applications of machine learning, we selected a total of eleven compounds that represented five 
drug classes ( 1. Ca
2+
 channel blockers, 2. adrenergic agonists, 3. cardiac glycosides, 4. human 
Ether-à-go-go-Related Gene (hERG) K
+
 channel blockers, and 5. angiotensin converting enzyme 
(ACE) inhibitors) along with one negative control compound from the database (Table 5.1). To 
the best of our knowledge, we reported for the first time the use of machine learning to establish 
a drug classification model based on hPSC-CM contractile behavior (half of the selected 
compounds) and subsequently demonstrated predictive capabilities by having the model classify 
unknown compounds (which was completely withheld from machine during any training). 
Compound Name MechanisticAction Tested Range (M) 
1) Nifedipine A L-type Ca
2+ channel blocker known to shorten action 
potential duration.92 
 
10
-8
 to 3.0x10
-5
 
2) Mibefradil A tetralol derivative that blocks both L- and T-type Ca
2+ 
channels. Shown to have higher affinity for T-type than 
L-type channels.93  
 
10
-9
 to 3.0x10
-6
 
3) Isoproterenol  A mixed beta-adrenergic agonists. Compound is 
nonselective in terms of beta receptors.94  
 
10
-8
 to 10
-4
 
4) Norepinephrine Mixed adrenergic agonist that stimulates both alpha- and 
beta-receptors.41  
 
10
-9
 to 10
-5
 
5) Digoxin A cardiac glycoside that inhibits that Na
+/K+-ATPase, 
resulting in higher intracellular Na+. Higher Na+ 
concentration suppresses the Na+/Ca2+ exchanger and 
causing the accumulation of intracellular Ca2+. 95 
 
10
-8
 to 10
-4
 
6) Ouabain A cardiac glycoside that affects Na
+/K+-ATPase, which 
consists of both alpha and beta-subunits. Has a lower 
affinity for alpha subunits than digoxin and other 
digitalis glycoside.95,96 
 
10
-8
 to 10
-4
 
7) Flecainide A mixed hERG K
+ blocker that also inhibits Na+ 
channels, causing effects on action potential’s 
repolarization and conduction.92 
 
10
-8
 to 10
-4
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8) E-4031 A pure hERG K
+ channel blocker known for pro-
arrhythmic potential.97 
 
10
-8
 to 10
-4
 
9) Cisapride A serotonin (5-HT4) receptor agonists that also inhibits 
the hERG K+ channel.98 
 
10
-8
 to 10
-4
 
10) Lisinopril An angiotensin converting enzyme (ACE) inhibitor , 
which reduces vasoconstriction and lowers blood 
pressure in patients.99 
 
10
-8
 to 10
-4
 
11) Ramipril An angiotensin converting enzyme (ACE) inhibitor. 
Unlike lisinopril, ramipril does not block ACE until it is 
converted by liver.100 
 
10
-9
 to 10
-5
 
12) Aspirin Common nonsteroidal ant-inflammatory drug that has 
been shown to have no cardioactive effects in screening 
platforms.30 
 
10
-8
 to 10
-4
 
Table25.1 Compound used in multi-class drug model 
 
5.5.2 Formation of hvCTS and drug treatment 
 Cardiomyocytes used for the hvCTSs were differentiated from a human embryonic stem 
cell line (hES2) with a protocol involving the sequential addition of BMP4, Rho kinase inhibitor, 
activing-A, and IWR-1, a Wnt inhibitor.
101
 To form hvCTS, cardiomyocytes at 14-16 post-
differentiation were dissociated and allowed to recover for 2 days. Afterwards, the cells at a 
density of 1 million cells per strip were combined with an extracellular matrix solution of bovine 
collagen I (2 mg/mL) and Matrigel (0.9 mg/mL) and human foreskin fibroblasts (10
5
 cells per 
strip). The cell-matrix solution (100 uL per tissue strip) was injected into a PDMS device and 
placed in an incubator (37 °C and 5% CO2). Formed tissue strips were fed with DMEM 
supplemented with 10% calf serum, 1% penicillin-streptomycin and 0.1% amphotericin B. The 
PDMS device contained flexible vertical posts of which the tissue anchors to and therefore shifts 
in position as the tissue beats. Contractile force measurements were captured with a high speed 
(100 fps) CCD camera while custom LabVIEW software tracked the centroid movement of the 
flexible pole tips. Force was derived from the deflection of the PDMS poles by the elastic beam 
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bending equation. This results in 𝐹 =  
3𝜋𝐸𝑅4
2𝑎2(3𝐿−𝑎)
𝛿 , where F, E, R, L, a and δ represent force of 
tissue contraction, Young’s modulus of PDMS, radius of posts, length of posts, height of the 
tissue on the post and measured tip deflection respectively.
102
  A custom MATLAB script was 
used to calculate 17 parameters that described the overall shape of the force traces for each 
contractile event (e.g. amplitude of curve) as seen in Table 5.2 and Figure 5.7. As some of the 
parameters are frequency-related (e.g. captured frequency), the calculated parameters for the last 
contractile event of each data acquisition was removed from the analysis.  
 
Examined Parameters 
1. Desired pacing frequency 7. 
Area under the curve of 
decline from max force to 
95% cutoff 
13. 
Area under the curve of 
decline from max force to 
50% cutoff 
2. Captured pacing frequency 8. 
Max change of force over 
time (∆F/∆T) of 
contraction phase 
14. 
Duration of rise from 25% 
cutoff to max force 
3. 
Max force generated 
(Amplitude) 
9. 
Max change of force over 
time (∆F/∆T) of relaxation 
phase 
15. 
Duration of decline from 
max force to 25% cutoff 
4. 
Duration of rise from 95% 
cutoff to max force 
(contraction phase) 
10. 
Duration of rise from 50% 
cutoff to max force 
16. 
Area under the curve of 
rise from 25% cutoff to 
max force 
5. 
Duration of rise from max 
force to 95% cutoff 
(relaxation phase) 
11. 
Duration of decline from 
max force to 50% cutoff 
17. 
Area under the curve of 
decline from max force to 
25% cutoff 
6. 
Area under the curve of 
rise from 95% cutoff to 
max force 
12. 
Area under the curve of 
rise from 50% cutoff to 
max force 
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Table35.2 Parameters derived from force traces of hvCTS 
 
Figure175.9 Cutoffs in force traces of hvCTS. Green line represents the amplitude. The left of the 
amplitude line is the contraction phase. The right of the line is the relaxation phase. 
 
After 7-8 days post tissue formation, hvCTS were exposed to drugs for 
pharmacodynamic analysis. The test compounds of cisapride, digoxin, E-4031, isoproterenol, 
mibefradil and ouabain were purchased from Sigma-Aldrich, while flecainide, lisinopril, 
norepinephrine and ramipril were provided by Pfizer. Compounds were initially re-suspended in 
DMSO and subsequently diluted in water for final concentrations composed of less than 0.1% 
(vol/vol) DMSO. All tested concentrations are reported in Table 5.1. The PDMS device 
containing the hvCTS was placed onto a heated stage (37° C) under a dissecting microscope. 
Before either vehicle or drug addition, the media was replaced with DMEM containing high 
glucose (4.5 g/L) and HEPES without phenol red. Drug doses were added to a tissue in 
consecutively increasing manner up to 10 concentrations with 3 minutes in between 
measurements. Vehicle doses containing only water were applied similarly. A pulse stimulator 
(AMPI Master-9) connected to platinum wires electrically paced the hvCTS with a monophasic 
electric field of 5 V/cm with a 10 ms duration. Force-frequency response was probed at each 
concentration for the range of unstimulated, 0.5, 1, 1.5 and 2 Hz.  
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5.5.3 Multi-class classification 
 To establish the drug classification model, we first determined which concentration of a 
chosen compound to add to the library. We gauged each compound’s level of cardioactivity by 
utilizing binary SVM as we did in Chapter 5 Section 4.
103
 To normalize for the increasing 
variation seen in hvCTS contractile behavior during the later serial additions of the vehicle 
studies, the SVM was performed between each concentration of a compound and the vehicle data 
from the corresponding serial addition number in which the concentration was achieved. For 
example, if a hvCTS was exposed to a cumulative 10 nM of compound on the 5
th
 serial addition, 
the collected data would be compared to the vehicle data recorded at the 5
th
 serial addition. 
Similar to our previous study, a non-linear kernel, radial basis function, was selected for the 
binary SVM. The hvCTS data was allocated with one third representing the test set and the 
remainder serving as the training set. We maintained a balanced number between the vehicle-
treated strips and those exposed to a cardioactive compound of the library (n = 6, 7, 8, 9, or 10). 
Since the number of vehicle strips (n = 28) always outweighed those treated with drugs, we 
randomly selected a subset of the vehicle-treated tissue strips that equaled in number for each 
SVM run. Again, we tuned both the box constraint and sigma parameter of each run with a 
geometric progression approach. To prevent overfitting, we performed a 5-fold cross validation. 
A total of 50 SVM runs were performed for each concentration to account for the variation and 
random selection of data sets. It should be noted that if more than half of the tissue strips become 
unresponsive to the electrical stimulation at a given concentration, the SVM accuracy for that 
condition was automatically designated as 100% and binary SVM was not performed.    
 In order to determine whether a concentration of a compound was inducing cardioactivity 
in the hvCTS, a non-cardioactive benchmark was first established by having a subset of vehicle-
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treated hvCTSs act as strips exposed to a non-cardioactive compound and subsequently 
comparing it to another set of vehicle-treated hvCTSs that served as a control. Thus, SVM 
accuracies for each serial addition of the vehicle study were generated 50 times for this 
benchmark. Then SVM accuracies of strips exposed to a drug condition were compared to those 
of the non-cardioactive benchmark by using a student T-test (a desired α value of 0.05) with a 
Bonferroni correction (m, the number of tests or hypotheses, was dependent on the number of 
drug additions in a screen). If the adjusted p-value was statistically significant, the drug condition 
was considered to have incited irregular behavior in hvCTSs and was labeled as cardioactive. 
The Bonferroni correction was also applied when examining changes in specific parameters.  
 For the multi-class classification, we then selected the compound concentration that met 
two criteria: 1) a binary SVM accuracy closest to 85% and 2) at least 6 of all screened tissue 
strips were still responsive to electrical stimulation. The criterion of 85% served as a reference 
point where the cardioactive effects of a compound would be prominent, but can still define a 
generalizable space and boundaries from those of other compounds. The value of 85% was 
specifically chosen as it was approximately the midpoint between the maximum achievable 
separation (100%) and a minimum bound that would ensure cardioactivity. We defined the 
minimum bound as the largest sum of mean SVM accuracy and one standard deviation across all 
vehicle studies, resulting in a bound of 69.34% (mean SVM accuracy of 53.45% and standard 
deviation of 15.89%). The criterion of at least 6 responsive tissue strips was to ensure that within 
the test sets there were data from at least two strips for all runs. As seen in Figure 1B, we then 
divided the compounds into two groups, one used to train the multi-class model and one 
representing ‘unknown’ compounds to be predicted. During this separation it was ensured that 
each class was at least represented by one compound within the two groups. For the training of 
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the model, we used an error-correcting output codes (ECOC) approach with the binary learners 
being SVM. The binary learners were again tuned in regards to the box constraint and sigma 
parameter. A 10-fold cross validation was performed on the entire model. To confirm the 
generalizability of the generated models, we randomly pre-allocated a third of the data as a test 
set prior to the training. Finally, we evaluated the multi-class model with this test set and then 
asked the machine to predict the classes of the contractile beats derived from the ‘unknown’ 
compounds group. Similarly, this multi-class classification and prediction process was repeated 
for a total of 50 times.  
To analyze the performance of the multi-class models, confusion matrices were generated 
for each of the 50 runs. In a confusion matrix, M, the precision and recall rate for each classifier 
were defined as the following: 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛𝑖 =  
𝑀𝑖𝑖
∑ 𝑀𝑖𝑗
𝑛
𝑗=1
 ; 𝑅𝑒𝑐𝑎𝑙𝑙𝑗 =
𝑀𝑖𝑖
∑ 𝑀𝑖𝑗
𝑛
𝑖=1
 . Within each matrix, 
the precision and recall rate were calculated for each of the classifiers. With these two metrics, 
the F1score, the harmonic mean of precision and recall, was calculated to summarize the 
performance of each classifier. The F1score is defined as the following: 𝐹1𝑆𝑐𝑜𝑟𝑒𝑖 =
 
2 × 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛𝑖 × 𝑅𝑒𝑐𝑎𝑙𝑙𝑖 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛𝑖+𝑅𝑒𝑐𝑎𝑙𝑙𝑖
.  A model that is perfect would achieve a F1 score of 1. If a model were 
composed of s-number of classes and had random classifiers, the expected F1 score would be 
1
𝑠
. 
To assess the model as a whole, accuracy, defined as 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦𝑚𝑜𝑑𝑒𝑙 =  
∑ 𝑀𝑖𝑖
𝑛
𝑖=1
∑ ∑ 𝑀𝑖𝑗
𝑛
𝑗=1
𝑛
𝑖=1
, was 
calculated. In summarizing the 50 runs of each model, all the calculated metrics were averaged 
and a confusion matrix containing the average number of contractile events over all runs was 
provided. All reported values in Chapter 5 Section 5.5 are in the format of mean + standard 
deviation.  All reported sample sizes (n) refer to independent tissue strips (biological replicates). 
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5.5.4 Control studies 
Although the hvCTSs were examined under temperature-controlled conditions, there was 
an observable change in contractile behavior of the vehicle-treated hvCTSs upon each serial 
addition. For example, the relative measured max force (amplitude) increased for all four pacing 
frequencies by an average of 16.96 + 0.83% upon the ninth serial addition (Figure 5.10B). To 
account and normalize for baseline drift, each drug condition was compared to its respective 
vehicle condition via binary SVM (e.g. measurements of the 7
th
 serial drug addition was 
compared to those of vehicle-treated hvCTSs at the 7
th
 serial addition). To establish that this 
methodology would create a benchmark of non-cardioactivity, a subset of the vehicle-treated 
hvCTSs were randomly selected to model a non-cardioactive compound. Binary SVM was then 
performed between the subset and a corresponding control group of equal size (n). To ensure that 
the number of hvCTSs in the subset had no effect, the calculations were done with n equal to 6, 
8, 9, and 10, which matched the range of numbers of striped used in each drug study of the 12 
tested compounds. As expected, the SVM accuracy, regardless of the size of n, was 
approximately 50% for all serial additions (Figure 5.10C). These results indicated that there 
were no consistent and distinguishable trends within each serial addition and thus, a reference of 
non-cardioactivity was created.   
 To validate this reference of non-cardioactivity, drug screens of aspirin from the database 
were used as negative controls. Aspirin is known to have no cardioactive effects on hPSC-CMs 
as this has been demonstrated in various platforms.
30,71,104–106
 As shown in Figure 5.10D, the 
SVM accuracies of the aspirin drug screens (n = 6) had an average of 52.85 + 1.77% among the 
9 serial additions (10 nM to 100 µM). None of the nine conditions were statistically different 
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from their vehicle counterparts, indicating that the binary SVM detected no drug-induced 
cardioactivity by aspirin.  
 
Figure185.10 Control experiments with hvCTS. A) hvCTSs were formed by the compaction of hPSC-
CMS, fibroblasts, and extracellular matrix solution around two PDMS poles. Force was derived from the 
deflection of the PDMS poles. B) The hvCTSs of the vehicle study exhibited a drift in contractile 
behavior after multiple serial additions of water. By the 9
th
 serial addition, the max force generated 
increased by 16.96 + 0.83% for all four pacing frequencies (n = 28). C) To normalize for baseline shifts in 
the vehicle, data from each drug conditions was compared to its respective vehicle condition (matching 
serial addition numbers). With this, a benchmark of non-cardioactivity was created with subsets of the 
vehicle-treated strips being modeled as strips exposed to non-cardioactive compounds. This subset was 
then compared to other groups of vehicle-treated strips with binary SVM. After 50 runs, the 
corresponding SVM accuracies served as the benchmark. The study showed that the number of tissue 
strips in the subset (n = 6, 8, 9, or 10) had no effect as the SVM accuracies for all conditions were 
approximately 50% for all serial additions. D) To assess non-cardioactivity benchmark, the data of 
aspirin-treated hvCTSs indicated no statistical difference from the vehicle study with an average 52.85 + 
1.77% among the tested range (n = 6). 
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5.5.5 Drug classification model 
In setting up the drug classification model, the eleven compounds were compared to 
vehicle-treated tissue strips with the aforementioned binary SVM approach. At one or more of 
the tested concentrations, all but two compounds, lisinopril and ramipril, had SVM accuracies 
that were greater than those of the respective vehicle studies with statistical significance (Figure 
5.11J & K). The ACE inhibitors, lisinopril and ramipril, did not have detectable cardioactive 
effects on hvCTS contractility, consistent with the results of other platforms.
105,107
 These non-
cardioactive results may have been anticipated as ACE inhibitors are primarily known to effect 
cardiovascular function through the relaxation of vascular smooth muscle and subsequent 
regulation of blood pressure, which is not present in the studied tissue model.
99
 Therefore, the 
ACE inhibitor class was therefore removed from the model resulting in a four class system. 
Overall, hvCTSs paired with the binary SVM approach demonstrated the capability in 
determining if a compound was cardioactive with great accuracy.  
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Figure195.11 Level of cardioactivity with screened compounds. Binary SVM was performed on the 11 
compounds including: A) nifedipine (p < 0.0063; n = 10) , B) mibefradil (p < 0.0063; n = 6), C) 
isoproterenol (p < 0.0055; n = 10), D) norepinephrine (p < 0.0055; n = 8), E) digoxin (p < 0.0055; n = 9), 
F) oubain (p < 0.0055; n = 10), G) flecainide (p < 0.0055; n = 8),  H) E-4031 (p < 0.0071; n = 8), I) 
cisapride (p < 0.0055; n = 9), J) lisinopril (p < 0.0055; n = 8), and K) ramipril (p < 0.0055; n = 7). Red 
circles indicate statistical significance in comparison to vehicle-treated hvCTSs. All listed p-values are 
already adjusted with a Bonferroni correction. 
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Mibefradil, norepinephrine, ouabain, and cisapride were chosen to represent the 
‘unknown’ compound group that the model would predict on. Mibefradil and cisapride were 
selected in particular as both compounds received market approval and were subsequently 
withdrawn.
62
 Thus, nifedipine, isoproterenol, and digoxin were chosen to represent the Ca
+2 
channel blocker, adrenergic agonist, and cardiac glycoside classes respectively. As both 
flecainide and E-4031 exhibit hERG K
+
 blocking capabilities, the impact of having either 
compound represent the hERG K
+
 blocker family was evaluated by generating the multi-class 
model under three different conditions: 1) flecainide as only representative, 2) E-4031 as only 
representative, and 3) both flecanide and E-4031 as representatives.    
 As previously mentioned, a subset of the data was always withheld from the machine 
prior to training in each of the runs. This withheld set quantified the generalizability in the 
models and ensured that overfitting had not occurred. Upon asking the machine to classify these 
test sets, the multi-class models demonstrated good generalizability by being able to correctly 
classify itself at an average accuracy rate of 76.09 + 6.43, 78.29 + 5.34, and 73.61 + 5.19% for 
the flecainide only, E-4031 only, and flecainide & E-4031 conditions respectively (Figure 5.12).  
In all three conditions, the multi-class models behaved similarly in that both the 
nifedipine and isoproterenol classifiers performed the best by always achieving the highest 
F1score values. This performance indicates that the data points of the nifedipine and 
isoproterenol compound occupied very distinct dimensional spaces, allowing for the binary 
learners to more accurately separate these compounds from others. At the same time, digoxin and 
the compounds representing the hERG K
+
 blocker had the lowest F1score values in all three 
conditions. These values would indicate that the data points of these compounds may occupy 
spaces that are near one another and possibly overlapping, making it more difficult for the 
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learners to separate between them. As a perspective of the quality of model performance, if there 
were absolutely no discernable differences among the four compounds for the machine to use, 
the expected values for precision, recall, and accuracy would be a rate of 25% (F1score would be 
0.25). Thus, the multi-class models created in all three conditions demonstrated good 
generalizability. In addition, as all three models behaved similarly, this would suggest that the 
choice of compound representing the hERG K
+
 blocker family had minimal effect on setting up 
the drug classification model.  
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Figure205.12 Generalizability of drug classification models. A) Condition 1: Flecainide was the 
representative compounds of the hERG K
+
 blocker family. Once the model was generated, its 
generalizability was evaluated by having it classify a withheld test set composed of compounds used to 
define the model. (Left panel) The confusion matrix displays the average number of classified contractile 
events over 50 runs and is imposed with a color scale that indicates precision rate. (Right panel) Metrics 
evaluating the performance are summarized in table. Metrics indicated good predictability as F1 scores 
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were above 0.6 for all classifiers. B) Condition 2: E-4031 was the representative of the hERG K
+
 blocker 
family. (Left panel) Confusion matrix indicated that all compounds were being correctly classified to 
themselves as the diagonal of the matrix had the highest precision rate. (Right panel) Metrics indicated 
similar performance between condition 1 and 2. C) Condition 3: Flecainide and E-4031 were the 
representatives of the hERG K
+
 blocker family.  (Left panel) Confusion matrix indicated no major effect 
on generalizability by having two compounds define a class. Precision rate was highest among the 
diagonal of the matrix. (Right Panel) Similar to condition 1 and 2, F1 scores were all above 0.6 indicating 
good generalizability of model. 
 
5.5.6 Prediction on unknown compounds 
With each condition’s drug classification model evaluated for generalizability, the 
machine was then asked to use each of these models to predict the data from the ‘unknown’ 
compounds group. In the first scenario with flecainide as the only hERG K
+
 blocker 
representative, the multi-class model was able to correctly label the four ‘unknown’ compounds 
to their corresponding counterparts with an average accuracy of 71.69 + 1.96% (Figure 5.13A). 
The four binary classifiers of this model demonstrated overall predictability by all having an 
average F1score above 0.6. The cardiac glycoside classifier (trained with digoxin data) had the 
highest score of 0.78 + 0.02 and the Ca
2+ 
channel blocker classifier (trained with nifedipine data) 
had the lowest at a value of 0.63 + 0.05, mainly attributed to a recall rate of 54.97 + 4.50%.    
 When the second drug class model (only E-4031 defining hERG K
+ 
blocker space) was 
used to predict the ‘unknown’ compounds, the average accuracy diminished to 65.37 + 2.33% 
(Figure 5.13B). This decrease was mainly the result of the contractile events from strips exposed 
to cisapride being miscategorized. Of the 779 contractile events of from hvCTSs exposed to 
cisapride, on average, 46.76 + 7.00% of the events were incorrectly labeled as hvCTSs affected 
by a cardiac glycoside. These misclassifications yielded a poor precision rate, 20.51 + 11.20%, 
and subsequently, a low F1 score, 0.27 + 0.11, for the hERG K
+ 
blocker classifier. As for the 
classifiers of the other three families, they performed comparably to those of the first condition 
and all had an average F1score over 0.6. These results indicate that using only data of hvCTSs 
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exposed to E-4031 is not sufficient in defining the hERG K
+ 
blocker family within a multi-class 
model and enabling that model to correctly predict cisapride’s mechanistic action.  
 In the last condition where the machine was trained with both flecainide and E-4031 
representing the hERG K
+
 blocker family, the average accuracy was 71.43 + 2.09%. All four 
classifiers had an average F1score higher than 0.6 (Figure 5.13C). Unlike the second condition, 
the hERG blocker classifier had a precision rate higher than 25% at 66.87 + 8.05%. The 
performance of this multi-class model was very similar to that of the first condition. In both 
scenarios, the macro-average of the F1scores was 0.71, demonstrating good predictability. These 
results suggest that the data points from the hvCTSs exposed to flecainide designated a 
dimensional space within the model that was similar to those of hvCTSs exposed to cisapride. 
Finally, the inclusion of E-4031 data with the flecainide data did not negatively impact the multi-
class model’s ability to correctly predict cisapride’s mechanistic action as neither the precision 
and recall rate fell below 41% as they did in second condition.   
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Figure215.13 Predictability of drug classification models. (A) Condition 1: Flecainide was the 
representative compounds of the hERG K
+
 blocker family. Models of all three conditions were evaluated 
for capabilities to predict drug families of compounds unseen by the machine. (Left panel) The confusion 
matrix displays the average number of predicted contractile events from the ‘unknown’ group over 50 
runs. Matrix shows that the ‘unknown’ compounds were classified to the correct drug family as the 
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precision rate was highest among diagonal of matrix. (Right panel) Model demonstrated good 
predictability as the macro-average of F1 score was 0.71. (B) Condition 2: E-4031 was the representative 
of the hERG K
+
 blocker family. (Left panel) Confusion matrix indicates that cisapride was predominantly 
being mislabeled as a member of cardiac glycoside family, represented by digoxin. Other three 
compounds were classified correctly to their respective drug families. (Right panel) The classifier of 
hERG K
+
 blocker class had a F1 score of 0.27, which is slightly better than a random classifier in a 4 class 
system (expected F1 score of 0.25). As the other three classifiers maintained a F1 score above 0.6, E-4031 
did not define a space that is shared with that of cisapride. (C) Condition 3: Flecainide and E-4031 were 
the representatives of the hERG K
+
 blocker family (Left panel) Confusion matrix indicates the model had 
good predicatability once flecainide was included again. Precision rates are highest among the diagonal of 
the matrix. (Right panel). The combination of having two compounds define a class did not affect the 
predictability of model. Condition 3’s model performed similar to condition 1 as it had a macro-average 
of 0.71, as well. 
 
5.5.7 Class relationship metrics 
 Aside from determining drug class, the concentration of a library compound that induced 
the most similar cardioactive effects as the compound of interest was determined. This metric 
was computed by first selecting the compound of interest at a desired concentration and 
performing a series of binary SVM among the tested range of a library compound. For each 
concentration of the library compound, the closer the SVM accuracy was to 50%, the more 
defined spaces of the compounds overlapped and the more similar the cardioactive effects were. 
This relationship between SVM accuracy and tested concentration range was presumed to 
behave in a Gaussian manner with the centroid representing the concentration that would elicit 
the most similar effects. The Gaussian fit was set with 50% as the lower limit and the highest 
achieved SVM accuracy as the upper limit. If the original SVM accuracies reached the 50% 
mark and remained around this value for subsequent concentrations, only the first concentration 
to reach the 50% was included in the fit to accurately model one side of the Gaussian curve.      
These relationship metrics are summarized in Table 5.3. For example, an estimated 
5.35x10
-5
 M of digoxin would be needed to evoke a level of cardioactivity that matches ouabain 
tested at 1.0x10
-5 
M. Such relationships could be of use as they provide insights on the potency 
of drugs. In the aforementioned example, ouabain would be considered to be the more potent 
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compound for that level of cardioactivity as it requires approximately 5-fold lower concentration. 
Such observation of ouabain’s higher potency is corroborated by the results seen in other in vitro 
data.
96,108
 The SVM accuracies and Gaussian fits related to these estimations are reported in 
Figure 5.14. 
Compound (M) Predicted Class 
Estimated Similar 
Concentration (M) 
Mibefradil (3.0x10
-6
) Ca
2+
 channel blocker Nifedipine (1.28x10
-7
) 
Norephinephrine 
(1.0x10
-5
) 
Adrenergic agonist Isoproterenol (1.44x10
-6
) 
Ouabain (1.0x10
-5
) Cardiac glycoside Digoxin (5.35x10
-5
) 
Cisapride (1.0x10
-4
) hERG K
+
 channel blocker Flecainide (1.03x10
-5
) 
 
Table45.3 Summary of estimated drug response relationships of all four classes. 
 
Figure225.14 Drug response relationships of ‘unknown’ compounds to compounds representing predicted 
classes using a binary SVM approach. Solid blue line indicates the binary SVM accuracy between a 
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concentration of the ‘unknown’ compound and each tested concentration of the representative compound. 
Dotted red line indicates a fitted Gaussian curve where the centroid represents the concentration at which 
the representative compound elicits the most similar response in the hPSC-CMs as the condition of the 
‘unknown’ compound. A) mibefradil and nifedipine (Ca2+ blockers), B) norepinephrine and isoproterenol 
(adrenergic agonist), C) oubain and digoxin (cardiac glycoside), and D) cisapride and flecainide (hERG 
K
+
 channel blocker). 
 
5.5.8 Improvements to predictability of drug model 
While the F1 scores of the established models already signified good predictability, there 
are still opportunities to further improve model performance and obtain F1 scores closer to 1, 
indicating better precision and recall rates with reduction in errors. The data in this study already 
suggests ways to do so. One method is to define each drug family with multiple compounds. By 
having only one compound define a class, there is a risk of only defining a partial space that the 
drug class entails. The data of E-4031 exemplified this when it was tasked of defining the hERG 
K
+
 blocker family. E-4031’s defined space did not match that of cisapride’s, another hERG K+ 
blocker, causing classification of cisapride to be closer to that of the cardiac glycoside family. 
The inclusion of flecainide, a mixed hERG blocker, with the E-4031 in the definition of the class 
allowed for the correct prediction of cisapride without adversely affecting the predictive 
capability of the remaining classes. Although the addition of E-4031 to the hERG blocker 
definition does not necessarily improve the predictive capability with respect to cisapride 
classification, establishing a more expansive dimensional space to define the hERG class may 
improve prediction of other unknown hERG blockers that have effects more similar to E-4031 
than flecainide.  These results also suggest the potential of having subgroups within classes of 
the model, which can be achieved through a series of multi-class classifications. For instance, a 
compound can be predicted as Ca
2+ 
channel blocker in the first classification. Within this family, 
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the compound can be subsequently categorized into a subgroup defined by frequency-dependent 
cardioactivity.  
In Figure 5.15A, a benchmark of non-cardioactivity was established by having a subset 
of the vehicle-treated strips represent a non-cardioactive compound and then asking the machine 
to separate this group from other vehicle-treated strips. The number of vehicle-treated strips was 
altered to see if this would affect the separation. There appeared to be no difference as all 
conditions had an average SVM accuracy of approximately 50%. However, as the number of 
tissue strips in each data set increased from 6 to 10, the standard deviation of the results 
decreased. Such results are comprehensible in that if a machine is provide more data, it would be 
able to create a more generalizable model and one that is less likely to overfit. Therefore, to 
further advance the predictability of the model, a larger number of hvCTSs per drug screen 
should be used for future models.  
Improvements of the multi-class drug models can also be achieved from enhancements of 
the hvCTSs and the acquisition system. In particular, the sensitivity of this system to positive 
inotropic compounds can be increased by addressing two issues, the maturity of stem-cell 
derived cardiomyocytes and the shifting baseline of vehicle-treated strips. Studies have shown 
that hPSC-CMs elicit a minimal to non-existent response to certain positive inotropic 
compounds, such as beta-adrenergic agonists, because of immature phenotypes.
39,43,44
 When 
these diminished responses are paired with a baseline that has increasing contractility over time, 
positive inotropic effects of a compound can get masked and harder to detect. This impediment is 
apparent in the isoproterenol drug screen. In Figure 5.15B, hvCTSs exposed to 10 µM of 
isoproterenol and paced at 0.5 Hz had a similar increase in max force to that of respective 
vehicle-treated strips (10.42 + 16.23% and 15.76 + 21.05% respectively), suggesting the 
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compound had no inotropic effects. However, isoproterenol’s cardioactive effects manifested in 
other parameters. For example, the duration of the relaxation phase or time from max force to 
95% cutoff decreased by 22.19 + 19.35% for the strips exposed to 10 µM isoproterenol, while 
those of the vehicle-treated strips experienced essentially no change. Even though machine 
learning was able to leverage these positive lusitropic effects in both binary and multi-class 
SVM, increasing the sensitivity of the system to positive inotropic effects would yield an even 
more distinct space for such compounds and subsequently better predictability in the drug 
classification models. While hvCTSs were already arranged in an anisotropic manner and co-
cultured with fibroblasts, they can be further matured through additional techniques: electrical 
stimulation prior to screens, a tri-culture including endothelial cells, or forced expression of 
selective proteins.
45–48
 As for the stabilization of the baseline, different components of the setup, 
ranging from pH to CO2 levels in ambient environment, should be re-evaluated to minimize 
overall drift within the serial additions. 
Interestingly, the hvCTSs treated with cardiac glycosides (digoxin and ouabain) also 
demonstrated the system’s sensitivity to positive inotropes. Typically these compounds induce an 
increase in amplitude in waveform (Ca
2+ 
transients or MEA); however, in this dataset, the strips 
treated with cardiac glycosides decreased in max force generated (amplitude) as the 
concentrations increased (Figure 5.15C).
47,75,109
 Such results could be attributed to cardiac 
glycoside toxicity or immature phenotype. Studies have shown that above 3 µM of digoxin or 
ouabain hPSC-CMs in monolayers stopped beating altogether.
70,75,110
 In this dataset, the highest 
concentration applied for both cardiac glycosides was 100 µM. At 100 µM of ouabain, 4 of the 
10 treated strips stopped beating at all pacing frequencies.  
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Similar to isoproterenol, a lack of increase in max force persisted in the strips exposed to 
lower concentrations of the cardiac glycosides; however, the cardioactive effects of these 
compounds appeared in the changes of other parameters. Such changes further highlight the need 
to look at multiple parameters. When the concentration of digoxin increased, the max force 
decreased while the duration of the relaxation phase increased. If limited to the observation of 
only these two parameters, one may believe that cisapride and digoxin are related in their 
cardioactive effects as cisapride-treated hvCTSs experienced similar trends in the two parameters 
(Figure 5.15D). But upon visual inspection of the force traces, it is evident that the compounds 
have distinct effects on hvCTSs caused by different mechanistic action (Figure 5.15E & F). The 
use of other parameters, such as the area under the curve of the relaxation phase, can easily 
summarize such differences. Changes in these parameters were clearly unique to the cardiac 
glycoside family as the ouabain-treated strips were correctly predicted from the other three 
classes. As seen in this study, machine learning is capable of analyzing all parameters and using 
those most critical in distinguishing a compound in a truly automated fashion. Because machine 
learning does not define drug classes with a priori knowledge (e.g. guidelines on how parameters 
are expected to change), the number of drug families and subclasses that can be defined within a 
model are not limited. This automation is also advantageous when a new drug family needs to be 
added into the library as no rubric needs to be manually amended and re-evaluated.    
While the concept of examining multiple parameters from waveforms has been pursued 
lately, some studies have suggested that only a few parameters (e.g. peak count) are necessary in 
assessing a compound’s cardioactivity as other parameters are derivatives of the select few and 
provide no further mechanistic insight.
70,71,111–114
 This is primarily true when the hPSC-CMs are 
spontaneously beating, meaning the force generated is linked to beating frequency. This study’s 
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dataset affirmed the importance of decoupling this force-frequency relationship through the 
pacing of the tissues. By setting a fixed pacing frequency, any changes to the force waveform 
can be truly accredited to a compound’s inotropic and lusitropic effects. For example, if the 
nifedpine-treated strips were allowed to spontaneously beat, a positive chronotropic effect would 
have most likely been observed.
17,43,92,108
 Because the hvCTSs displayed a negative force-
frequency relationship, a decrease in max force could not be directly linked to chronotropic or 
inotropic effects or a combination of both. When 0.3 µM nifedipine-treated hvCTSs were paced 
at 1 Hz, the captured frequency of the tissue was 0.99 + 0.01 Hz and the max force decreased by 
45.69 + 10.42% (Figure 5.15G). This paced data confidently confirmed nifedipine had a 
negative inotropic effect on the tissues. However, a limitation of this study’s drug models is the 
absence of spontaneously beating hvCTSs’ responses to cardioactive compounds. This data 
would provide understanding of a compound’s chronotropic effects. Even though the model has 
already demonstrated good predictability on inotropic- and lusitropic-related data alone, the 
model would benefit from chronotropic-related data as it would provide more dimensions in 
which the compounds can further distinguish themselves and yield better predictability.       
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Figure235.15 Examination of various compounds’ cardioactive effects. A) In the vehicle study, hvCTSs 
paced at 0.5 hZ continually increased in max force generated through subsequent serial additions. The 
duration of decline from max force to 95% cutoff, relaxation phase, was unaffected by the number of 
serial additions. (n = 28). B) Isoproterenol-treated hvCTSs experienced an increase in max force similar 
to the vehicle-treated strips, suggesting no inotropic effects. Isoproterenol’s lusitropic effects were 
apparent as duration of the relaxation phrase decreased with significant differences respective to the 
vehicle study at concentration range of 3.0x10
-7
 to 10
-5
 M (p < 0.0055; n = 10). C) Digoxin-treated 
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hvCTSs (paced at 0.5 Hz) experienced a decrease in max force and an increase in duration of relaxation 
phase by the highest concentration, 10
-4
 M (p < 0.0055; n = 9).  D) Cisapride-treated hvCTSs (paced at 
0.5 Hz) experienced similar trends in max force and duration of relaxation phase by the highest 
concentration, 100 µM (p < 0.0055; n = 9). E) Representative force tracing of a contractile event from a 
digoxin-treated hvCTSs (paced at 0.5 Hz) show the distinct cardioactive effects prolonging the duration 
while increasing the area under the curve of the relaxation phase. F) Representative force tracing of a 
contractile event from a 100 µM cisapride-treated hvCTSs (paced at 0.5 Hz) show that while cisapride 
and digoxin have similar trends in certain parameters, the cardioactive effects of the two are visibly 
distinguishable. G) Nifedipine-treated hvCTSs had capturing frequencies that matched the pacing 
frequency of 1 Hz from 10-8 to 3.0x10-7 M. During this concentration range, the max force generated 
decreased by 45.69 + 10.42%. Since the force-frequency relationship was decoupled by pacing the strips, 
it can be concluded that the decrease in force is attributed to the compound’s negative inotropic effects (p 
< 0.0063; n = 10). All listed p-values are adjusted with a Bonferroni correction. 
 
 
5.6 Summary 
 In this chapter, the utility and flexibility of machine learning was shown through the 
analyses of data from two different screening platforms, vectors outputted from optical flow of 
brightfield videos and force traces of hvCTSs. Machine learning applications to cardiotoxicity 
screening has been primarily in silico rather than the assessment of cardiomyocyte functionality 
to compounds.
115,116
 Machine learning techniques offer the advantage of simultaneously 
evaluating multiple parameters and any underlying relationships, which may lead to better 
detection of cardioactivity. Without the need for guidelines and rubrics, machine learning can 
provide information in an automated manner that would facilitate in the streamlining of the drug 
discovery pipeline. Notably, we have shown that binary SVM can generate a quantitative 
singular index that describes a compound’s level of cardioactivity and provide drug response 
relationships between compounds. Using multi-class classification, models of drug families were 
established and used to predict the mechanistic action of unknown cardioactive compounds 
(which were completely withheld from the machine). While functional, the analyses of both 
platforms were meant to exhibit the potential of machine learning in providing further insights in 
the detection of cardioactivity using hPSC-CMs. The basis of the models was an ECOC 
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approach with the binary learners being SVM. Different binary learners, such as decision trees, 
should be explored alongside completely different approaches (e.g. neural networks). Other 
machine learning approaches and techniques may provide additional information relevant to 
evidence based decision-making for drug development. Importantly, an ideal machine learning 
technique will need to balance predictive capabilities and use of computational resources. 
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CHAPTER 6: Analysis of 3D cardiac organoid chambers 
6.1 Introduction 
 Along with platforms differing in their methodology of monitoring hPSC-CM behavior, 
the tissue geometry in these systems also greatly contrasts. Certain platforms employ hPSC-CMs 
in a two dimensional manner (e.g. monolayer), while others choose to recapitulate aspects of the 
three dimensional environment of native myocardium by modeling the cells as cardiac muscle 
fibers or fascicles.
27,35,46,74
 Regardless of geometry, the majority of these platforms have 
presented adequate capabilities of capturing the effects of chronotropic and inotropic agents 
within hPSC-CMs. However, there exist compounds where the cardioactive effects become most 
apparent when observing the heart’s ability to pump in a stable and rhythmic manner. Each heart 
beat is comprised of electrical stimulation of the four heart chambers in a sequential manner. 
Any disturbances to the electrical propagation can alter pumping functions and more 
importantly, the amount of oxygenated blood delivered to the body. Compounds, such as 
dromotropic agents, can perturb the conduction velocity at the atrioventricular (AV) node, 
leading to arrhythmic events and sudden cardiac deaths.
117,118
  Tissues with 2D geometry (e.g. 
monolayer) or those that model cardiac muscle fibers (e.g. hvCTS in Chapter 5) cannot observe 
such compounds’ effects on pumping mechanism. Thus, there is still a need to create systems 
that can recapitulate the three-dimensionality of the heart on the level of organs.  
 Dr. Kevin Costa’s research group has shown a way to create bioartificial pumps, referred 
to as cardiac organoid chambers (COC). These COCs exhibits pumping functions and a 
geometric shape similar to a chamber of the human heart, which is currently not present in most 
3D cardiac organoids. Traditionally to quantify the COC, pressure readouts from a transducer is 
required. As the readouts are one dimensional, they do not necessarily capture the spatial 
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changes of the organoid as the electrical propagation occurs. While optical mapping techniques 
can be performed, the dyes, as mentioned in Chapter 1, can be cytotoxic and prevents 
longitudinal studies. In this chapter, we show that the brightfield techniques described in Chapter 
2 can be readily applied to videos of COCs exposed to a cardioactive compound and provide key 
spatial information not present in pressure readouts.  
   
6.2 Cardiac organoid chambers   
The COC is prepared by casting a gel mixture of collagen, basement membrane matrix, and 
cells into a cup-shaped mold. Both neonatal rat cardiomyocytes and hPSC-CMs along with 
respective fibroblasts have been demonstrated with the COC. Prior to the gel polymerization, a 
silicone balloon catheter with the tip cut off is placed concentrically in the mold and inflated to 
the desired size. After 24 hours of incubation, the gel and catheter are then placed in medium. 
Within 7 to 10 days, the gel will have compacted into a network of cardiac tissue around the 
catheter.
119
 
The COCs spontaneously beat and generated cyclic changes in chamber pressure. Via 
measurements with electrodes, voltage signals with distinct spikes and subsequent slow 
repolarizations were present. As seen in Figure 6.1A, a pressure-area loop was formed with a 
counter-clockwise direction, indicating positive stroke work. To demonstrate the Frank-Starling 
mechanism, the mean chamber pressure was increased and as a result, the developed pressured 
from the spontaneous beating increased in a near linear relationship.
119
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Figure246.1 Cardiac organoid chamber A) COC after 7 days of incubation.  B) Pressure-area curves 
derived from measurements of the COC. The counter clockwise motion indicates positive stroke work, a 
pumping characteristic of the human heart. C) As mean chamber pressure increased, the developed 
pressure within the COC increased. This positive trend indicates a functional Frank-Starling mechanism. 
Adapted from Lee, E. J., Kim, D. E., Azeloglu, E. U. & Costa, K. D. Engineered cardiac organoid 
chambers: toward a functional biological model ventricle. Tissue Eng. Part A 14, 215–25 (2008) with 
permission from Mary Ann Liebert Inc. 
. 
6.3 Drug responses with COC’s 
 A set of videos capturing the effect of isoproterenol on a spontaneously beating COC 
were provided for analysis. The COC was formed with 10 million cells and had a diameter on the 
centimeter scale. The videos were captured at 100 frames per second with a resolution of 1024 x 
1024 pixels for a total of 30 seconds. Furthermore, the COC was illuminated by a single light 
source with a dark background. Isoproterenol was administered to the COCs at an increasing 
concentration of 10, 100, 1000 and 10
4 nM. Prior to analysis, the COC in each frame was 
segmented from the dark background (image was thresholded into a black and white image) and 
superimposed onto a white background with grids. This pre-processing step improved the signal 
to noise ratio. Afterwards, the videos were processed with the optical flow technique described in 
Chapter 2 Section 2.3.1. A contractile plot was then derived by performing PCA on the 
corresponding vectors.   
The obtained signals for all tested concentrations are shown in Figure 6.2. As expected 
the beating frequency of the control measurement (approximately 0.6 Hz) increased with the 
86 
 
administered concentration of isoproterenol. At the highest concentration of 10 µM, the beating 
frequency (0.93 hZ) increased by 1.55 fold, demonstrating the compound’s chronotropic effects. 
In addition, the amplitude of the contraction phase by 10 µM increased by 61.44% relative to the 
baseline, suggesting greater contractility. These results are consistent with the known 
cardioactive effects of isoproterenol and were confirmed with the pressure data captured 
(increase in both frequency and max pressure developed).  
 
 
Figure256.2 PCA analysis of COC exposed to isoproterenol. As the concentration of isoproterenol 
increases, the beating frequency and amplitude of the contraction phase of the COC increase. Such 
changes are consistent with isoproterenol’s cardioactive effects.  
  
While the PCA analysis of the optical flow vectors complemented the pressure data, it 
did not provide the spatial information that is missing from the pressure readouts. As a result, we 
investigated the vectors themselves as they are composed of magnitudes and directionality. To 
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determine a reference point for analysis, we used the contractile plots and selected the peak of 
the contraction phase for each contractile event (Figure 6.3A). We then aggregated all the 
vectors of each peak and binned them by their directionality (to the nearest whole degree). In 
each bin, the magnitudes of the vectors were summed and displayed in a polar coordinate plane 
as seen in Figure 6.3B & C. At the baseline measurement, the COC appeared to prefer two 
directions (upwards and to the right) at this reference point of contraction. However, at the point, 
the COC when exposed to 10 µM had a preference for only the upwards direction, indicating that 
besides beating faster and stronger, the pumping mechanism of the COC was spatially altered.  
 In order to confirm this, the vectors generated from optical flow were plotted over the 
images of the COC. In Figure 6.3D & E, the frame at which the peak occurred for a contractile 
event is shown. In this image, it is observed that the bottom of the COC was contracting upward 
and the right wall of the organoid was distending outward. In the corresponding image that 
represents the COC exposed to 10 µM of isoproterenol, only the bottom of the organoid was 
contracting upward with the right wall showing reduced motion. As these images agree with the 
polar plot, it is evident that the brightfield technique can be applied to the monitoring of COCs 
and track changes to the organoid’s pumping from a spatial perspective. This information can be 
critical in screening for compounds that disrupt electrical propagation across the cardiac surface 
(e.g. reentrant arrhythmia) and have its cardioactive effects primarily manifest in the perturbation 
of the heart’s pumping capabilities. 
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Figure266.3 Spatial information regarding contraction of COC. A) The optical flow vectors were examined 
for spatial information to describe the contraction of the COC. A reference point, the peak of the 
contraction phase, was chosen. B) All the vectors at each peak were binned by their directionality (to the 
nearest whole degree). In each bin, vectors’ magnitudes were summed and displayed in a polar coordinate 
plane. At baseline, it appears that the COC had two preferential directions, upwards and to the right. C) At 
10 µM, only one preferential direction, upwards, was seen indicating changes in pumping pattern. D) 
Vectors were overlaid over original image. At one of the peaks, the upwards direction referred to bottom 
of the COC contracting (Green Trace). The rightward direction was the right wall distending out (Blue 
Trace). E) Visual inspection of the COC exposed to 10 µM isoproterenol at the peak reference point 
showed that the right wall was no longer distending (Blue Trace).  
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6.4 Summary 
 While hPSC-CM tissues with simple geometry (e.g. monolayer or spheroidal clusters) 
offer the high-throughput capabilities to screen for cardioactivity, there is still a need for 
organoids that recapitulate the pumping functions of the heart. A subset of cardioactive 
compounds elicit their effects the most pronounced at the organ level. The COC developed by 
the Costa group offers a solution as the organoid chamber exhibits positive stroke work and the 
Frank-Starling mechanism. In this chapter, we have preliminarily shown that the brightfield 
approach with optical flow (previously used for monolayer cultures) can be applied to videos of 
COC. The optical flow vectors can capture changes to the way COC pumps with spatial 
resolution, which the one dimensional pressure readouts cannot provide. This capability provides 
a potential method to screen for compounds (e.g. dromotropic compounds) that perturb electrical 
propagation across the cardiac surface. However, the brightfield approach with optical flow still 
needs to be optimized for COC videos. Through the analysis of other COC videos, the high 
frame rate of 100 fps is very sensitive to environmental noise (surrounding vibrations) and 
granularity in images (imbalance between light source, camera gain, and quality of camera 
sensors). As optical flow assumes constant brightness, videos of COCs should be taken in a 
standardized manner, such as consistent light sources, set working distance between lens and 
object, and a space that minimizes vibrations (e.g. optical table). With this standardization, the 
brightfield approach can be utilized on the COC videos to provide information-rich readouts for 
the screening of cardioactivity.  
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CHAPTER 7: Summary and future work 
7.1 Summary of the work 
 In this work, we present a strategy to create a platform for enhanced detection of drug 
induced-cardiotoxicity with human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs). 
We provide both hardware- and software-based solutions that address pitfalls that current 
platforms experience. To monitor the behavior of hPSC-CMs exposed to cardioactive 
compounds, we incorporated a brightfield technique that leverages optical flow to quantify 
videos of cardiomyocytes beating (Chapter 2). This combined approach is non-invasive, 
allowing for longitudinal studies, and it requires minimal equipment. As hPSC-CMs express a 
fetal-like phenotype, we propose a biomimetic substrate to align cells along the substrate’s 
anistropic wrinkled surfaces (Chapter 3). The alignment of cardiomyocytes has been shown to 
invoke phenotypes more similar to the native myocardium. hPSC-CMs seeded on the wrinkled 
substrates demonstrated a more sensitive response to cardioactive compounds. In consideration 
of commercial use, the substrates were adapted for high-throughput capacity by patterning 
multiple islands of cardiomyocytes that act as independent samples within a single surface 
(Chapter 4). In order to analyze the complex yet rich data provided by screening platforms, a 
holistic approach in supervised machine learning was implemented (Chapter 5). Machine 
learning has the advantage of simultaneously evaluating multiple parameters and any underlying 
relationships. Utilizing both binary and multi-class SVM, we have developed a suite of tools that 
can determine an unknown compound’s level of cardioactivity, predict its cardioactive 
mechanism and report its drug response relationship to other compounds. Finally, we further 
demonstrate the flexibility of the brightfield technique by analyzing videos of a 3D tissue model, 
cardiac organoid chamber (Chapter 7). The optical flow vectors provide spatial information 
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regarding the organoid’s pumping, which can be crucial in screening compounds that disrupt the 
electrical propagation across cardiac surfaces.   
 
7.2 Concluding remarks 
 In this dissertation, hardware and software components were designed to resolve various 
challenges of current screening platforms that employ hPSC-CMs. All of the components are 
modular such that they can be easily and independently applied to existing platforms for 
improved detection of drug-induced cardiotoxicty. At the same time, these components can and 
should be integrated into a single system to collectively leverage each component’s advantages. 
If the system were to be created, it should be constructed as an organ-on-a-chip that can be easily 
connected to chips that model other organs within a single network. One of the major reasons for 
drug-induced cardiotoxicty in market approved drugs is unexpected rises in serum levels of 
unmetabolized compounds. Typically, the body is able to metabolize a compound via isozymes 
found in the liver, kidney, skin, gastrointestinal tract and lungs. However, when a patient is 
taking multiple medications, drugs can compete for the same enzyme receptor site and therefore 
cause elevated concentrations in circulation.
120
 For example, mibefradil was withdrawn due to its 
potentially fatal drug-drug interactions with 25 other medications. Through the competition of 
cytochrome P450 3A, increased concentration of mibefradil resulted in the prolongation of the 
QT interval and the possibility of cardiotoxicity-related deaths. With a network of organ-on-a-
chips, it may be feasible to predict drug-drug interactions and estimate therapeutic windows in an 
in vivo setting, leading to better preclinical detection of drug-induced cardiotoxicity.  
 Through the emergence of various methodologies to monitor hPSC-CM behavior when 
exposed to cardioactive compounds, it has become evident that in order to accurately predict a 
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compound’s in vivo cardiotoxic effects,  a consortium of platforms examining different aspects 
or phenotypes (e.g electrophysiology, contractility, or cell shape) of cardiomyocytes will be 
required.
75,104,121
  This concerted effort is due to the various ways drug-induced cardiotoxicity 
occurs. The work in this dissertation has referred to some of these ways, ranging from drug-drug 
interaction to manifestation of cardioactive effects on the organ level through the perturbation of 
pumping mechanisms. The presented machine learning approaches can be used on different 
forms of signals (e.g calcium transients, MEA and optical recordings) and has the potential to 
integrate data of multiplex systems or even those across platforms. Moreover, machine learning 
can be utilized on a grander scale by incorporating past clinical data to determine the optimal 
combination of in vitro and in silico data for the prediction of drug-induced cardiotoxicity in 
patients.   
 Lastly, a key advantage of using stem cell-derived cardiomyocytes is the opportunity for 
personalized medicine. Specifically, chemotherapeutic agents, such as doxorubicin and the 
anthracycline family, can cause cardiotoxicity that is irreversible and cumulative dose-
dependent.
122
 However, the cardiotoxic effects of such agents vary from person to person. Dr. 
Joseph Wu’s research group has recently shown that patient induced stem cell-derived 
cardiomyocytes were able to recapitulate the prevalence of doxorubicin-induced cardiotoxicity 
that matched patients’ clinical data.123 The ability to asses a compound’s propensity to induce 
carditoxicity in a specific patient will allow physicians to create a custom theraputic regimen best 
suited for each patient. The methods proposed in this dissertation can be readily applied to create 
a high-throughput platform suitable for personalized medicine, as well.  
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